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Abstract 
For the delivery of hydrophilic macromolecules, a novel flexible, hydrophilic delivery system 
based on gelatin nanoparticles is developed. Stabilization of gelatin in water is addressed 
using an apolar zero length crosslinker, i.e., diisopropylcarbodiimide (DIC). Crosslinking of 
GNPs with polar crosslinkers has certain limitations not only crosslinking gelatin 
nanoparticles but also the loaded proteins, which interfere not only in the release of cargo but 
also their biological activity. Therefore, we introduced a novel crosslinking approach termed 
as interfacial crosslinking with the application of DIC which specifically crosslink the 
colloidal interface and not diffusing into the interior of nanoparticle. In this context, critical 
process parameters involved in the crosslinking process have been investigated in order to 
obtain optimum preparation conditions.  
The main challenge while formulating these surface crosslinked gelatin nanoparticles 
(scGNPs) was purification. The centrifugation results in the formation of non-redispersible 
pellet. Therefore, we optimized tangential flow filtration as a promising alternative 
purification tool. 
For the final proof of our hypothesis that the hydrophobic crosslinker crosslink only the 
colloidal interface of GNPs without  crosslinking the loaded protein, the surface crosslinked 
GNPs were loaded with a model hydrophilic protein, i.e., lysozyme. This proved scGNPs as a 
flexible delivery system for protein-based drugs. 
  
   Zusammenfassung 
XVII 
Zusammenfassung 
Gelatine-Nanopartikel haben sich als eines der geeignetsten Wirkstoffträgersysteme für 
hydrophile Makromoleküle erwiesen, insbesondere für Therapeutika auf Proteinbasis. 
Während der Formulierung ist die Vernetzung von Gelatine-Nanopartikeln (GNPs) ein 
unvermeidlicher Stabilisierungsschritt, der mit unerwünschten Konsequenzen einhergeht, die 
die GNPs zu einem weniger flexiblen Trägersystem für proteinbasierte Moleküle machen. 
Wasserlösliche Quervernetzer verknüpfen nicht nur die Gelatine, sondern auch die 
enthaltenen Biologicals. Dies beeinflusst nicht nur ihre Freisetzung in vivo, sondern führt 
auch zum Verlust der biologischen Aktivität. Im Rahmen dieser Arbeit wurde ein Ansatz zur 
Vermeidung dieser unspezifischen Reaktion untersucht. Es wurde eine alternative 
Stabilisierungsstrategie eingeführt: die Grenzflächenvernetzung unter Verwendung des 
apolaren Quervernetzers Diisopropylcarbodiimid (DIC). Ziel war es, GNPs zu entwickeln, die 
nur an ihrer Oberfläche vernetzt sind. In diesem Zusammenhang wurden verschiedene am 
Vernetzungsprozess beteiligte Prozessparameter untersucht, um optimale Herstellungs- und 
Reaktionsbedingungen zu finden. 
Eine Hauptherausforderung bestand in der Aufreinigung der stabilisierten Partikel. 
Zentrifugation resultierte in einem nicht aufschüttelbaren Pellet weswegen die 
Tangentialflussfiltration (TFF) etabliert werden konnte. 
Das System konnte erfolgreich mit dem hydrohpilen Modellprotein Lysozym beladen werden 
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1.1. Introduction 
The field of molecular biotechnology with the help of latest technologies, such as, 
combinatorial chemistry and high-throughput screening, has produced a significant number of 
active pharmaceutical compounds (APIs). Majority of these APIs are hydrophilic 
macromolecules which are regarded as novel therapeutic compounds being used for the 
treatment of numerous major pathologies, such as cancer and cardiovascular disease. 
These macromolecular therapeutic compounds include recombinant proteins, antisense 
oligonucleotides, genes and small interfering RNAs [1]. Amongst these novel therapeutic 
compounds, protein-based active pharmaceutical ingredients are being predominantly utilized 
in clinics [2]. These hydrophilic proteinaceous compounds offer many advantages as 
compared to small molecules which include high potency, low unspecific binding, minimum 
toxicity and low probability of drug–drug interaction [3]. Their significance is, however, 
hampered by lack of effective, safe and specific delivery.   
1.2. Delivery challenges of macromolecules 
The delivery of these macromolecules to the desired site of action is affected by certain 
obstacles which, consequently, lead to a low biological half-life at the desired site of action. 
These obstacles decrease the therapeutic potential and clinical applications of these potent 
therapeutic compounds. Some of the major obstacles associated to delivery of these 
compounds are structure instability, short in vivo half-life due to extensive first-pass 
metabolism as well as the phagocytic metabolism and low permeability across biological 
membranes [3-5]. Some of the important challenges associated with delivery of 
macromolecular drugs have been elaborated in Figure 1-1. Therefore, in order to achieve the 
highest therapeutic efficacy of macromolecules, appropriate and effective delivery systems 
are needed. 
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Figure 1-1. Challenges of macromolecular drug delivery (adapted from Agrahari V et al. 
(2016) [2]). 
 
1.3. Nanoparticle-based delivery of hydrophilic macromolecules 
For the effective treatment of human illnesses, the delivery of therapeutic proteins specifically 
to the diseased sites is a rate limiting factor [2]. The conventional administration of these 
compounds require comparatively high dose due to non-specific bio-distribution and fast 
metabolism of free drugs before reaching to their targeted sites. To overcome these 
challenges, nanoparticulate delivery systems have been demonstrated as a promising 
alternative for the delivery of macromolecules, peptides and nucleic acid-based molecules [6, 
7]. The nano-size dimension of these particle systems enhance the intracellular uptake as 
compared to larger carriers [8, 9]. Besides, these nanoparticulate formulations offer 
advantages over conventional drug delivery systems. These include higher bioavailability at 
the target site due to enhanced solubility of low solubility drugs [10-14], reducing the side 
effects of chemotherapeutic drugs due to a localization at the site of action by the enhanced 
permeability and retention (EPR) effect [15] and controlling the release of drug and 
enhancement of permeation of drugs across the cell membrane [16]. However, these 
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nanomaterials are mostly composed of hydrophobic polymers, which possess some demerits. 
They may cause unfolding and hence inactivation of protein-based hydrophilic 
macromolecules [17-19]. Furthermore, they also have low encapsulation potential for the 
hydrophilic protein based drugs [20, 21]. Due to this fact, water soluble polymers of natural 
origin have always been under investigations as a delivery vehicle for these sensitive 
macromolecular drugs [22, 23]. Different types of biopolymeric materials including 
polysaccharides (e.g., chitosan, dextran), and proteins (e.g., albumins, gelatin, gliadin, zein, 
soy protein, etc.) have been investigated as a constitutive materials of these nanoparticles. The 
selection criteria of appropriate nanoparticle materials depends on several factors including 
(a) the desired size of nanoparticles (b) the physicochemical properties of drug, e.g., aqueous 
solubility and stability (c) desired drug release profile (d) surface charge (e) immunogenicity 
and toxicity of the final product and (f) biodegradability and biocompatibility of the fabricated 
nanomaterials [24]. In recent years, the protein-based biopolymeric nanoparticles have offered 
numerous advantages due to some desirable attributes such as low toxicity and 
biodegradability [25]. They have been exploited both for pharmaceutical as well as 
nutraceutical delivery [26]. 
1.4. Proteins as a construction material for nanoparticles 
Protein-based nanomaterials possess excellent biocompatibility and biodegradability [27]. 
Nanoparticles formulated from proteins are biodegradable, metabolizable, and provide 
excellent opportunities for surface modification by attaching different targeting ligands [28]. 
They can be prepared from both water soluble proteins (e.g., bovine and human serum 
albumin) and water insoluble protein (e.g., gliadin, zein) [29, 30]. 
Albumins and gelatins were the first naturally occurring proteins from which protein 
nanoparticles were fabricated [31-33]. The albumin- and gelatin-derived colloidal systems are 
promising due to biodegradability, low immunogenicity [34] and non-toxicity. They show 
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high stability in biological environment [35]. Various nanoparticle formulations prepared from 
proteins have been displayed in Table 1-1.  
Table 1-1. Compiled research investigations for numerous active loaded protein nanoparticles 
Proteins Source Delivery system  Reference 
Albumin bovine serum 
human serum 
nanospheres and nanocapsules [36-39] 





Gliadin: wheat gluten 
Legumin: pea seeds 
oral and topical drug systems. 
Used in the mucoadhesive 
formulations 
[29, 40] 
Elastin Connective tissue Nanoparticles [41] 
Zein Maiz (corn) Nanoparticles formed from 
zein proteins to encapsulate 
bioactive compound (e.g., 
coumarin, 5-fluorouracil).  
[30, 42, 43] 
Β-lactoglubulin 
& Casein 
Milk  [44] 
Soy Proteins Soybeans  [45, 46] 
 
1.5.  Gelatin as a construction material for delivery systems 
Gelatin is a hydrophilic bio-macromolecular polymer which is obtained from collagens of 
mammals, e.g. bovine and porcine sources. Besides, gelatin from fish and marine sources has 
also been used [47-49]. It is isolated after denaturation of collagen using partial acidic or 
alkaline hydrolysis. It has widespread applications in pharmaceuticals, cosmetics and food 
industry with high level of safety. Due to its biodegradability and biocompatibility, it is 
generally regarded as safe (GRAS) material by the United States Food and Drug 
Administration (FDA) [50-52]. It possesses a highly heterogeneous molecular weight 
distribution consisting of mixture of water-soluble protein fragments of different molecular 
masses. There are two types of gelatin, i.e., type A and type B. Type A gelatin is manufactured 
from porcine skins after its acidic treatment. This acidic treatment does not cleave the amide 
bonds of asparagine and glutamine residues of the collagen. This leads to a higher isoelectric 
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point ( IEP), i.e., 7-9 [53]. On the other hand, gelatin B is obtained from bovine hides and skin 
with alkaline treatment. This alkaline treatment cleaves the amide bonds of asparagine and 
glutamine to aspartate and glutamate, respectively. The production of higher amounts of 
acidic amino acids leads to a greater proportion of carboxylic groups which make type B 
gelatin as negatively charged protein at neutral pH. Consequently, this leads to lowering of 
IEP (i.e., 4.5–6.0) [54]. In the field of drug delivery, gelatin has been exploited as a 
fabrication material for different delivery systems [55] which include hydrogels [56], films 
[57], microcapsules [58] and nanoparticles [59, 60]. 
1.5.1. Gelatin nanoparticles as a carrier for hydrophilic macromolecules 
Gelatin nanoparticles (GNPs) have been repeatedly reported in the literature as carrier system 
for a wide range of therapeutic compounds. These include peptide-, non-peptide- and gene-
based therapeutic compounds. Some of the non-peptide-based compounds include paclitaxel 
[61], pilocarpine [62], amphotericin B [63], FITC-dextran [64], methotrexate [65], cytarabine 
[66], hydrocortisone [62], doxorubicin [67-69], didanosine [70], sulphamethaxazole [71], 
cyclosporine [72], rosiglitazone [73] and cycloheximide [74]. 
GNPs have been exploited as an excellent delivery platform for a variety of protein- and 
peptide-based drugs. Some researchers have reported bovine serum albumin as a model 
proteinaceous cargo for GNPs without causing any physicochemical instability to protein 
primary structure [75]. In another attempt, a composite delivery system composed of BSA-
loaded GNPs which were subsequently microencapsulated in poly (lactic-co-glycolic acid) 
microspheres. This composite architecture was found promising in terms of maintaining a 
sustained release pattern and the ability to prevent the denaturation of protein [76]. In another 
study, FITC-BSA was encapsulated in  recombinant human gelatin (rHG) nanoparticles which 
showed safety, sustained release and lower degree of initial burst release [77]. Some other 
examples of proteins encapsulation in GNPs are angiogenic basic fibroblast growth factor 
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(bFGF) [77], insulin [78], alkaline phosphatase (ALP) [79], tissue-type plasminogen activator 
(t-PA) [80, 81] and bone morphogenetic protein-2 (BMP-2). All these formulations utilizing 
GNPs as a carrier system for different proteins retained the in vitro biological activity of the 
encapsulated protein-based drugs.  
The GNPs have also been proven as a promising carrier system in immunotherapy. It has been 
reported that GNPs are effectively and significantly up-taken by murine bone marrow 
dendritic cells (DCs) and therefore, they are intended for targeting antigens to dendritic cells, 
hence acting as an immunoadjuvant [26]. Following the subcutaneous administration of 
tetanus toxoid (TT)–encapsulated GNPs in BALB/c mice, the systemic immune response was 
effectively stimulated. This was confirmed by a comparable amount of IgG production in the 
mice blood circulation. In contrast to conventional alum-TT vaccine, the cytokine response 
expressed in terms of IL-2 and IFN γ level was significantly higher [82]. After uptake by 
antigen presenting cells (APC), these TT vaccine-loaded GNPs are digested by enzymes 
present in the lysosomal compartment (e.g., collagenase) thus releasing the tetanus toxoid 
payload intracellularly. Another advantage is that GNPs can be loaded with a large amount of 
antigens, therefore, leading to an antigen specific immunological response. 
The first gelatin nanoparticulate-based formulation was carried out by C. Oppenheim et al., 
employing coacervation-phase separation using sodium sulphate as a coacervating agent [33]. 
It was observed that the gelatin nanodispersion system obtained with simple coacervation 
possess broader size distribution and colloidal instability. Since then, various formulation 
approaches have been adopted depending upon the intended application in order to get 
physicochemically stable colloidal gelatin particles. The drug substances can be loaded to 
these nanocarriers either prior to nanoparticle formation via incorporation to gelatin aqueous 
solution or by post-nanoparticle formation via electrostatic adsorption. The former method 
has been found to be more effective in terms of encapsulation efficiency. Since, gelatin 
nanoparticles have multiple functional groups due to its proteinaceous nature which provides 
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excellent opportunities for modification, e.g., attachment of targeting-ligands and crosslinkers 
[83-85]. There are numerous formulation methods which have been reported so far for the 
preparation of gelatin nanoparticles. Some of the commonly used methods are elaborated as 
following.  
1.5.1.1. Formulation methods of GNPs  
Coacervation-phase separation 
In coacervation-phase separation, nanoparticles are formed as a result of liquid-liquid phase 
separation from a homogeneous solution of charged macromolecules. In fact, two 
distinguishable phases are formed. The polymer rich, dense phase (coacervate phase), tends to 
sediment at the bottom and a relatively transparent layer in the supernatant layer [86]. The 
phase separation is initiated following the addition of salt, e.g., sodium sulphate to aqueous 
gelatin solution containing surfactant, e.g., tween 20 followed by addition of isopropanol to 
dissolve the precipitate by sodium sulphate. Subsequently, the sub-microparticles are 
crosslinked by the addition of glutaraldehyde. This leads to formation of gelatin particles in 
the size range of 600 to 1000 nm [86]. 
Emulsification-solvent evaporation 
In this approach, an aqueous phase containing gelatin and drug is emulsified with organic or 
oil phase, e.g., polymethylmethacrylate [65, 66] or paraffin oil [87] forming an water-in-oil 
emulsion system (w/o) accompanied by vigorous shaking. Afterwards, the emulsion system 
consisting of gelatin nano-droplets as a dispersed phase is crosslinked after addition of 
glutaraldehyde [65] or genipin [87]. Finally, the dispersion medium (organic phase) is 
evaporated leaving behind GNPs (100 to 400 nm) [65].  
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Reverse Phase Preparation Technique 
Reverse phase involves the formation of gelatin nanoparticles after encapsulation of gelatin 
aqueous solution inside the core of reverse micellar droplets made by surfactant bis (2-
ethylhexyl sulphosuccinate) in n-hexane [88]. Subsequently, the entrapped gelatin aqueous 
solution is crosslinked with a crosslinker. With this method, gelatin nanoparticles in the range 
of 40 nm can be formulated [88]. 
Inverse Mini-emulsion Technique 
Inverse mini-emulsions approach is characterized by the formation of gelatin nanoparticles 
employing two inverse mini-emulsion systems, i.e., mini-emulsion A and mini-emulsion B. 
Emulsion A consists of gelatin droplets in p-Xylene stabilized by tween 80 as an emulsifier. 
Emulsion B is obtained after emulsification of the aqueous phase of crosslinker agents, e.g., 
glutaraldehyde or carbodiimide/N-hydroxysuccinimide (CDI/NHS) in p-xylene as dispersion 
medium. Both types of crude emulsions are sonicated to get a homogeneous dispersion 
system. Subsequently, both crude emulsions are mixed together in an ice bath with continuous 
sonication. This leads to fusion of the droplets thus forming crosslinked gelatin nanoparticles. 
The working principal of the inverse mini-emulsion is fusion and fission which is responsible 
for the formation of nanoparticles [89-91]. With this technique, GNPs in the size range of 
150-200 nm can be produced with a relatively broad size distribution [91]. 
Desolvation Technique 
In the desolvation technique, the gelatin solution is dehydrated following the addition of a 
dehydrating agent, e.g., alcohol or acetone to an aqueous gelatin solution. Desolvation 
involves transition from stretched conformation to coil conformation. Afterwards, crosslinkers 
are added to gelatin nanoparticles for stabilization [92, 93]. The main disadvantage of this 
technique is that it leads to formation of large particles with in-homogeneous size distribution 
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due to heterogeneity in molecular weight of gelatin. In order to solve this problem, two-step 
desolvation was introduced by Coester et al., [26]. With two step-desolvation, smaller 
nanoparticles with a narrower distribution are obtained. In two step desolvation, the high 
molecular weight gelatin fragments are extracted in the first desolvation step from low 
molecular weight gelatin. Then, the high molecular weight gelatin is re-dissolved and 
desolvated again. With two-step desolvation, GNPs with a size of 100-300 nm are obtained 
[94, 95]. 
Nanoprecipitation Technique 
The nanoprecipitation technique is also known as solvent displacement technique. It involves 
two miscible solvents; the solvent phase in which the polymer is soluble and the non-solvent 
phase in which the polymer is not soluble containing poloxamer as a stabilizer. While 
producing gelatin nanoparticles via nanoprecipitation, gelatin is dissolved in water and is then 
slowly added to an organic solvent, e.g., methanol, ethanol, acetone or acetonitrile which act 
as non-solvent containing poloxamer as a stabilizer. Due to instantaneous diffusion of the 
solvent phase into the non-solvent phase, interfacial turbulences are created which forms 
nanodroplets at the interface. Finally, the gelatin polymer precipitates within these droplets 
which ultimately lead to formation of nanoparticles. Subsequently, glutaraldehyde is added to 
crosslink the nanoparticles [96, 97]. Nanoprecipitation has many advantages. It is a rapid, 
straightforward and easy to perform technique. It enables the production of nanoparticles in 
the size range of 250-350 nm with narrow unimodal distribution [98]. Nanoprecipitation does 
not involve shear forces, sonication or very high temperatures, which could inactivate the API 
and it does not involve the formation of oily–aqueous interfaces also known to impair protein 
drug functionality [99]. These interfaces are known to interfere with the three dimensional (3-
D) structure and function of encapsulated proteins ultimately leading to loss of intended 
activity [99-101]. 
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It is evident that the physicochemical stabilization via chemical crosslinking is common to all 
the above mentioned production methods. It is because the un-crosslinkd GNPs are readily 
dissolved on contact with hydrophilic environment. 
1.5.2. Crosslinking of gelatin nanoparticles 
Due to hydrophilicity, gelatin-based delivery systems dissolve in aqueous environment and 
thus cannot maintain its structural integrity without crosslinking. Therefore, crosslinking of 
gelatin nanoparticles is indispensable in order to get mechanical stability in aqueous 
environment, shape and enhanced in vivo circulation time [50, 93]. The un-crosslinked GNPs 
have been found to be unstable and consequently, they tend to dissolve in the aqueous media 
with the passage of time [102]. Different methods to crosslink GNPs have been reported and 
are described in the following.  
1.5.2.1. Aldehydes 
The literature survey shows that glyoxal-induced crosslinked GNPs exhibits an instantaneous 
mass aggregation which results in precipitation of nanoparticles [103]. Therefore, in order to 
avoid these instabilities, researchers have demonstrated glutaraldehyde as an alternative 
effective crosslinker for stabilization of GNPs [64, 67]. The GNPs crosslinked with 
glutaraldehyde show stability for more than 10 months at 2–8 °C. Glutaraldehyde is a homo-
bifunctional crosslinker forming poly- or bi-functional crosslinks into the protein network by 
bonding free amino groups of lysine or hydroxylysine amino acids, known as Schiff’s base 
[67, 104] (see  Figure 1-2). As glutaraldehyde becomes a part of the crosslink, therefore, a 
very low amount remained unreacted, hence the residual crosslinker is removed following 
particle purification. In order to avoid the expected toxicity associated with glutaraldehyde, 
another aldehyde, D, L-glyceraldehyde is regarded as a non-toxic crosslinking agent. The D-
enantiomer is normally metabolized in the body through glycolytic pathway following 
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phosphorylation by triokinase producing D-glyceraldehyde-3-phosphate. The metabolite, D-
glyceraldehyde-3-phosphate, is an important intermediate of the glycolytic pathway. In the 
near past, the DL-glyceraldehyde induced crosslinked gelatin was recognized as a new 
material for pharmaceutical purposes [105]. In this connection, insulin-loaded GNPs 
crosslinked with DL-glyceraldehyde were synthesized being intended for pulmonary 
administration. After subcutaneous as well as intra-tracheal administration of nanoparticles 
into rats, no toxicity was observed [78]. Nevertheless, some level of toxicity has been reported 
in oral toxicology studies as well as skin dermatitis when used in skin applications. Therefore, 
it has always been a demand to use non-toxic crosslinking agents for stabilization of GNPs 
[106]. 
 
Figure 1-2. Mechanism of glutaraldehyde-based crosslinking of gelatin forming Schiff’s bases 
within gelatin peptidal chains. 
1.5.2.2. Genipin 
In order to avoid the toxicities arising from glutaraldehyde, it has always been a topic to 
search for less toxic crosslinkers. One such example is genipin which is a natural crosslinker 
obtained from gardenia fruit. Genipin has been demonstrated to be 10,000 times less toxic 
than glutaraldehyde [107]. The crosslinking time with genipin is longer and the crosslinking 
involves the bond formation between two free amino groups of lysine residue on the protein 
molecule with one molecule of genipin [108]. One such example is the genipin-crosslinked 
rHG nanoparticles which showed an effective internalization into the cells without any 
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significant cytotoxicity [77]. The crosslinking reaction mechanism of genipin within the 
gelatin fragments can be schematically represented in Figure 1-3. 
 
Figure 1-3. Mechanism of genipin induced crosslinking of gelatin. A. Fast nucleophilic attack 
of gelatin’s L-lysine amino groups on the ring structure of genipin to form a stable transition 
intermediate product; and B. slower reaction with nucleophilic substitution of free lysine 
amino molecules of a second gelatin chain (Adapted from James B Rose et al. 2014 [109]). 
1.5.2.3. Carbodiimide/N-hydroxysuccinimide (CDI/NHS)  
A mixture of two water soluble carbodiimide, carbonyldiimidazole (CDI) and N-
hydroxysuccinimide (NHS) was employed as crosslinking mixture for the stabilization of 
GNPs [110]. The crosslinking mechanism of this crosslinking mixture has been illustrated in 
Figure 1-4. As a result, nanoparticles with relatively smaller sizes and narrower size 
distribution with smoother morphology are obtained as compared to GNPs crosslinked with 
glutaraldehyde. In this research, paracetamol was used as a model drug. The drug entrapment 
as well as loading efficiencies were higher in the CDI/NHS crosslinked nanoparticles. The 
release kinetics profile was comparable to that of glutaraldehyde (GTA)-crosslinked 
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nanoparticles. Other physicochemical differences between glutaraldehyde-crosslinked GNPs 




Figure 1-4. Mechanism of crosslinking caused by CDI/NHS crosslinkers (adapted from 
Qazvini et al., 2011 [110]). 
1.5.2.4. Microbial transglutaminase (MTG) 
The enzyme-based crosslinking is a promising strategy owing to high specificity of the 
enzyme catalysis. This catalysis is controlled to a certain extent by changing pH and 
temperature [111]. The crosslinking of GNPs with recombinant microbial transglutaminase 
(MTG) was investigated by Fuchs et al., [112]. The GNPs were formulated by a two-step 
desolvation technique using acetone as a desolvating agent followed by crosslinking with 
microbial transglutaminase. The MTG favours the formation of intra- and intermolecular 
isopeptide bonds within the protein networks by connecting the ε-amino groups of lysine with 
the amide group of glutamine. This enzyme-catalysed crosslinking reaction is accompanied 
by the elimination of ammonium ion (NH4
+
) as a by-product (see Figure 1-5). The optimum 
temperature for the MTG-catalysed crosslinking reactions was observed to be at 25 °C at a 
neutral pH using an ion-free solvent. With this approach, GNPs with a mean size below 250 
nm and narrow size distribution were produced successfully [112]. 




Figure 1-5. Microbial transglutaminase catalysed crosslinking reaction in gelatin 
nanoparticles. This involves the conjugation of primary amino groups of glutamine and 
lysine. During this crosslinking, one mole of ammonium is produced (adapted from S. Fuchs 
et al., (2010) [112]). 
1.5.3. Purification methods of nanoparticles 
After preparation of nanoparticles, purification is a necessary step to remove the toxic un-
wanted substances present in the crude nano-dispersion systems. These include chemical 
initiators, crosslinkers, excessive amounts of stabilizers and un-encapsulated APIs. Purified 
nanoparticles also minimize the variability in biological applications. The characteristic 
features of an effective and efficient purification procedure is that it should remove 
satisfactorily all the above mentioned impurities from the nanoparticles suspensions without 
influencing the physicochemical properties of nanoparticles such as size, shape and surface 
charge. 
Some of the reported purification method are: size exclusion chromatography [113], size 
selective precipitation [114], magnetic field flow fractionation filtration [115], cross-flow 
filtration [116], electrophoresis [117], density gradient centrifugation [118] and centrifugation 
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[119]. Gel filtration chromatography, ultra-filtration and centrifugation are most commonly 
reported purification methods for polymeric nanoparticles. The main disadvantage of these 
methods is the problem of scale up of these methods. On the other hand, ultra-filtration-based 
purification can be automated and hence cost effective for industrial purposes.  
1.5.3.1. Centrifugation based purification 
Large amounts of impurities can be removed from the nanodispersion system using 
centrifugation followed by re-dispersion in water. This is a straightforward method, but 
sometimes it leads to formation of non-dispersible aggregates of nanoparticles. Another 
disadvantage is the low yield of nanoparticles due to loss of finer nanoparticles in the 
supernatant [120]. Therefore, centrifugation is applicable to purification of nanoparticles on 
laboratory scale, but is not applicable to for industry applications [120]. 
1.5.3.2. Tangential flow filtration  
Tangential flow filtration (TFF) also known as crossflow filtration, has been frequently 
reported for the purification of proteins [121]. Since the size dimensions of nanoparticles are 
almost in the same range as proteins, therefore TFF-based ultrafiltration can also be employed 
effectively for the purification of nanoparticles [116, 120]. The difference between normal or 
dead-end) flow filtration and tangential flow filtration is the direction of the flow (see Figure 
1-6). By pumping the feed tangentially along the membrane, the pressure which is built up 
due to particles on the membrane that can pose a problem in normal flow filtration, is 
minimized. Particles that are too large to pass the membrane are swept along, instead of 
accumulating at the membrane surface.  
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Figure 1-6. Comparison between (a) dead-end or normal flow filtration and (b) tangential 
flow filtration. 
 
During cross-flow filtration, the starting particles suspensions known as feed will be divided 
into two solutions, the retentate and the filtrate. The retentate (also known as concentrate) is 
composed of particles which are too large to pass through the membrane and therefore are 
retained. In normal flow filtration, the retentate consists only of large particles, but because of 
the tangential flow, some solute and small molecules will be pushed past the membrane, and 
make the retentate a concentrated one. The retentate can be either collected in a separate 
vessel, or returned to the feed vessel. The solutions passing through the membrane is called as 
filtrate or permeate, as the membrane is permeable for it (see Figure 1-7). Tangential flow 
filtration can be performed in either concentration or diafiltration mode (Figure 1-7). In 
concentration mode, the feed volume is reduced by filtration, and thereby the particle 
concentration increased. On the other hand, during diafiltration, the suspension volume is kept 
constant by adding new buffer as filtrate is removed. By doing so, buffer exchange is possible. 
As the buffer is exchanged, all undesired species that were dissolved in it, will be removed. 
This is why filtration is a potentially good method for purification of nanoparticles. In this 
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Figure 1-7. TFF-based ultra-filtration in (a) concentration mode and (b) diafiltration mode. 
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The aim of this thesis can be divided in three work packages. In the following diagram, these 
work packages are briefly summarized. 
 
 
Figure 2-1. Summary of the work packages addressed in the present thesis. 
2.1. Formulation optimization for the design of surface-crosslinked gelatin 
nanoparticles (scGNPs) 
Majority of the hydrophilic macromolecules are proteins in nature, therefore, the 
nanoparticulate-based formulation should guarantee the maximum physicochemical stability 
as well as biological activity of the encapsulated macromolecular compound. In most of 
preparation techniques for gelatin nanoparticles reported so far, the stabilization with 
hydrophilic crosslinker is common. These hydrophilic crosslinkers, e.g., glutaraldehyde, 
glyoxal, genipin, enzymatic crosslinking, etc., are mostly used to gain mechanical stability in 
aqueous environment. The demerit of hydrophilic crosslinkers is that due to their non-specific 
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crosslinking of the gelatin networks with the loaded cargo, they cause interference in the 
release of loaded hydrophilic drug from the gelatin matrix [122]. Therefore, the core objective 
was to physicochemically stabilize the gelatin nanoparticles, using zero-length hydrophobic 
crosslinker, diisopropylcarbodiimide (DIC). The idea is to avoid diffusion of crosslinker into 
the hydrophilic interior of nanoparticles. This will provide an opportunity to encapsulate 
protein-based drugs. In this context, the formation of gelatin nanoparticles using both gelatin 
A and B was carried out using nanoprecipitation technique followed by crosslinking with a 
hydrophobic zero-length crosslinker to obtain surface crosslinked gelatin nanoparticles that 
are stable in aqueous environment. The hypothesis of the surface crosslinking caused by zero 
length hydrophobic crosslinker, i.e., diisopropylcarbodiimide was investigated in terms of 
both direct measurements as well as indirect measurements. The direct measurements are 
concerned about the evaluation of crosslinking degree of crosslinked GNPs using TNBS assay 
to quantify the un-crosslinked primary amino groups in gelatin matrix after crosslinking 
GNPs with diisopropylcarbodiimide. On the other hand, the indirect measurements involve 
the determination of residual amounts of the crosslinker (DIC) remained unreacted in the 
crosslinking of GNPs and the amounts of crosslinking by-product of this crosslinker, i.e., 
diisopropylurea formed in the mixture after completion of crosslinking reaction. For these 
investigations, validated methods of gas chromatography and proton NMR spectroscopy were 
employed.  
To get a stable formulation, some critical parameters were investigated such as optimum 
crosslinker concentration, optimum crosslinking time and crosslinking reaction temperature 
with regard to the effect on particle size, size distribution and zeta potential of gelatin 
nanoparticles.  
Aim and Scope of the Thesis 
22 
2.2. Optimization of purification procedures for the surface-crosslinked GNPs 
After establishing a validated formulation composed of DIC-surface crosslinked GNPs 
following the standard formulation optimized in work package 1, the next step was the 
purification of these novel gelatin-based nanocarriers systems from hazardous impurities, e.g., 
unreacted crosslinker, i.e., diisopropylcarbodiimide, it’s by product known as diisopropyl urea 
(DIU) and the stabilizer (Poloxamer 188). Centrifugation is the most frequently used 
purification tool for nanoparticles. However, in some situations, centrifugation results in the 
formation of a hard pellet which cannot be easily re-dispersed in water. This phenomenon is 
mostly observed when the organic solvents (e.g., acetone, alcohol) are the dispersion phases 
of polymeric nanoparticles. In our scenario, the DIC-crosslinked GNPs are also non-
dispersible in water following centrifugation because of dispersion medium which is 
predominantly acetone. 
Therefore, in order to avoid the formation of non-dispersible pellet and to avoid particle loss 
as well, we evaluated and optimized the performance of tangential flow filtration (TFF) for 
the purification of DIC surface-crosslinked gelatin nanoparticles and compared the results 
with dialysis and centrifugation. During the optimization of TFF-based purification, the 
influence of different process parameters, e.g., membrane type, pore size and amount of 
recirculating water on physicochemical properties of DIC-crosslinked GNPs was evaluated. 
Besides, the effectiveness of TFF-based purification in terms of removal of aforementioned 
hazardous impurities from the DIC-crosslinked GNPs suspensions was also focussed in this 
chapter. 
Aim and Scope of the Thesis 
23 
2.3. Characterization and loading of surface-crosslinked GNPs with hydrophilic 
macromolecules 
This work package is mainly focused on the provision of more experimental evidences in 
order to prove the working hypothesis of surface-crosslinking. This would be possible in 
terms of loading these surface crosslinked gelatin nanocarriers with a model hydrophilic 
therapeutic protein-based payload. For this purpose, lysozyme was selected as model protein in 
the present study. The main aim of this investigation was the evaluation of crosslinkability of 
loaded protein-based cargo (i.e., lysozyme) with the nanoparticulate matrix composed of 
gelatin. The hypothesis was characterized in terms of recovery of encapsulated lysozyme after 
performing in vitro release experiment and also monitoring the biological activity of loaded 
lysozyme. For comparison, the glutaraldehyde crosslinked GNPs loaded with similar amount of 
lysozyme were also evaluated for in vitro release extent and biological activity of the released 
lysozyme. So, in both types of crosslinked GNPs, i.e., glutaraldehyde and DIC-crosslinked 
GNPs, the biological activity of loaded lysozyme was evaluated after releasing the lysozyme in 
phosphate buffer saline (PBS) to make sure whether the polypeptide after undergoing a few 
formulation steps, i.e., co-precipitation with gelatin, nanoencapsulation in GNPs and 
crosslinking with DIC and glutaraldehyde, retains its intended biological activity or not. 
Besides, a non-peptide based hydrophilic macromolecular cargo, i.e., FITC dextran was also 
loaded into these DIC-surface crosslinked GNPs to investigate the in vitro release kinetics 
pattern of non-peptidal hydrophilic macromolecular drugs from these novel types of surface-
crosslinked GNPs and subsequently comparing with glutaraldehyde-crosslinked GNPs. 
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3.1. Abstract  
This chapter is focused on the formulation development of surface-crosslinked gelatin 
nanoparticles thus providing a flexible hydrophilic nano-delivery platform for both peptide-
and non-peptide-based hydrophilic macromolecular drugs. The physiochemical stabilization 
of gelatin nanoparticles is achieved while employing the zero-length hydrophobic crosslinker, 
diisopropylcarbodiimide. The basic idea is that the hydrophobic crosslinker cannot diffuse 
into the interior of the nanoparticle due to its apolar nature rather than it would establish the 
crosslinks on the surface of nanoparticles after conjugating primary amino groups of lysine 
and hydroxy-lysine with the carboxylic acid groups of aspartate and glutamate residues of the 
gelatin matrix. So far, we have developed a new methodology for the physicochemical 
stabilization of gelatin nanoparticles through a selective and diffusion limited crosslinking 
process using diisopropylcarbodiimide as a crosslinker. The formation of GNPs was carried 
out following the standard protocols of nanoprecipitation. Subsequently, the crosslinker 
diisopropylcarbodiimide was added to the nanosuspension followed by overnight (20-24 h) 
mixing to favour crosslink formation in gelatin nanoparticles. The crosslinking process was 
optimized both for type A and type B gelatin with different bloom numbers and 
concentrations and its possible impact on the physicochemical properties of gelatin 
nanoparticles. The gelatin nanoparticles fabricated from type B gelatin possess mean sizes of 
200 - 300 nm and a narrow size distribution (PDI < 0.2). On the other hand, type A gelatin 
leads to formation of surface-crosslinked nanoparticles which possess mean sizes of 200 –
 500 nm (PDI <0.2) depending upon the bloom number and the concentration of gelatin used. 
To assure the biocompatibility, cytotoxicity against A549 cells was conducted which indicated 
no significant toxicity up to 1 mg/mL.  
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3.2. Introduction  
Until now, different formulation approaches have been adopted for the design of gelatin 
nanoparticles. These methods have been discussed in chapter 1 in section 1.5.1.1. Since, 
gelatin is a hydrophilic biopolymer; therefore, on contact with aqueous environment, these 
gelatin nanoparticulates cannot maintain their mechanical and structural integrity. 
Consequently, they swell up and rapidly dissolve in the aqueous medium. Therefore, 
crosslinking is the necessary step for the physicochemical and mechanical stabilization of 
these GNPs in hydrophilic environments. For this purpose, different hydrophilic crosslinkers 
have been used which have already been discussed in detail in chapter 1 section 1.5.2. 
The demerit of these hydrophilic crosslinkers is that due to their non-specific crosslinking of 
the gelatin networks with the loaded cargo, they may cause interference in the release of 
loaded hydrophilic macromolecular drugs from the gelatin matrix. Besides, the activity of 
encapsulated protein-based drug molecule is also affected after crosslinking. Therefore, a 
novel strategy for the stabilization of gelatin nanoparticles is needed.  
Keeping under consideration this non-specific crosslinking caused by these hydrophilic 
crosslinkers, we intended to crosslink gelatin nanoparticles on the colloidal interface of GNPs 
using hydrophobic zero-length crosslinkers in order to avoid the diffusion of crosslinker 
inside the nanoparticles’ matrix. To the best of our knowledge, the stabilization of GNPs with 
the application of hydrophobic zero-length crosslinkers is not reported so far. The aim of this 
study was to design nano-sized hydrophilic gel (gelatin)-based particles (GNPs) using the 
previously established standard protocols of nanoprecipitation [123]. Following the 
nanoprecipitation, the gelatin nanoparticles were crosslinked with hydrophobic crosslinker to 
overcome the main drawback for flexible protein delivery. For this selective interfacial 
crosslinking of GNPs, we employed diisopropylcarbodiimide (DIC) which is a zero-length 
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hydrophobic crosslinker. The basic idea is that the crosslinker (DIC) due to its hydrophobicity 
may not diffuse into the core of nanoparticle rather than it would cause its crosslinking action 
on the colloidal interface following the conjugation of primary amino groups with the 
carboxylic functional groups which are present on the colloidal interface of un-crosslinked 
GNPs. This conjugation leads to formation of amide-bonds between the polypeptide chains of 
gelatin on the surface of GNPs. These crosslinks provide stability to the GNPs in hydrophilic 
environment and at the same time avoid crosslinking of the proteinaceous payload in the 
carrier.  
Furthermore, the formulation was optimized with respect to different process parameters, e.g., 
crosslinker concentration, crosslinking time and crosslinking reaction temperature with regard 
to the effect on particle size, size distribution and zeta potential. The nano-formulation of 
surface-crosslinked GNPs was optimized both for type A and type B GNPs. As type B gelatin 
acts as anionic biopolymer at pH 7 while type A as a cationic biopolymer, which offer good 
opportunity to load both positively and negatively charged hydrophilic macromolecules.  
3.2.1. Challenges of GNPs crosslinking 
Since gelatin’s peptidal chains are interconnected through covalent bonds after treatment with 
chemical crosslinkers as discussed in section 1.5.2, the crosslinked gelatin nanoparticles 
maintain their structural integrity in the aqueous media [124].The main disadvantage of these 
hydrophilic crosslinkers is their non-specific crosslinking behaviour. Due to the polar nature, 
the crosslinkers diffuse into the core of the nanoparticles after crossing the colloidal interface. 
This results also in crosslinking of the loaded macromolecules if the respective chemical 
functional groups are present (NH2). These newly established crosslinks are either intra-
molecular (protein cargo-protein cargo crosslinks) or inter-molecular (protein cargo-gelatin 
molecule crosslinks) [125], see Figure 3-1 for non-specific crosslinking. Consequently, this 
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non-specific crosslinking lead to a potential interference in the release of loaded hydrophilic 
macromolecular drugs from the gelatin matrix [67] as well as to diminished biological activity 
of the encapsulated bioactive compound. Therefore, it is judicious that this non-specific 
crosslinking impedes the effective loading and hence the utilization of gelatin nanoparticles as 
a delivery tool for hydrophilic macromolecular APIs [126]. 
 
 
Figure 3-1. (a) Schematic illustration of glutaraldehyde-crosslinked GNPs loaded with a 
protein-based drug. (b) A closer look of Schiff’s base crosslink between gelatin and protein-
based drug substance. 
 
In order to avoid this non-specific crosslinking dynamics due to the application of hydrophilic 
crosslinkers, it is demanded to use hydrophobic crosslinkers which should specifically and 
selectively crosslink the colloidal interface of GNPs only without diffusion into the core of 
GNPs. 
In this research work, I will introduce a novel stabilization mechanism, termed as surface 
crosslinking of GNPs by using a zero-length hydrophobic crosslinker; DIC. This thesis is 
aimed to prove the hypothesis that the hydrophobic crosslinker (DIC) would localize its 
crosslinking action on the colloidal interface of GNPs rather than diffusing into the interior of 
the nanoparticle (NP) due to its hydrophobic nature. These surface-crosslinked GNPs will 
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provide a flexible delivery system for protein-based therapeutic compounds as the load will be 
affected only to a minor extent. 
3.3. Experimental  
3.3.1. Materials 
Gelatin type B Bloom 75 from bovine skin, gelatin type A from porcine skin with three 
blooms (90-100, 175 and 300), Poloxamer 188 and diisopropylcarbodiimide (reagent grade) 
were purchased from Sigma-Aldrich (Steinheim, Germany). Acetone was obtained from 
Fischer Chemicals Ltd., (Loughborough, U.K). Milli-Q water with a resistivity of 
18.2 MΩ.cm
 
was used throughout the experiments. Tangential flow filtration (TFF) cassettes 
fitted with modified regenerated cellulose material (hydrosart) with molecular weight cut-off 
(MWCO) of 100 kDa was purchased from Sartorius Stedim Biotech Ltd. (Goettingen, 
Germany). The validated procedure of TFF-based purification will be discussed in detail in 
the next chapter 4. 
3.3.2. Nanoparticles by nanoprecipitation  
Gelatin nanoparticles were formulated using the pre-established  formulation recipe based on 
nanoprecipitation technique [123]. Briefly, the solvent phase was obtained  after dissolving 20 
mg of gelatin in 1 mL of Milli-Q water at 50 °C. Subsequently, the solvent phase was added 
dropwise to the anti-solvent phase consisting of acetone containing poloxamer 188 (3 % w/v) 
as a stabilizer. Afterwards, the GNPs were crosslinked with different amounts of 
diisopropylcarbodiimide solution in acetone from its stock solution (69.16 % [w/v] for 
varying crosslinking time intervals. As a last step, the crude nanosuspension was washed 
employing tangential flow filtration (TFF) to remove impurities. The validated procedure of 
TFF-based purification will be discussed in detail in the next chapter 4. For the measurements 
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of the zeta potential, the TFF-based purified particles were used while for optimization of 
crosslinking conditions; GNPs without purification were analysed for DLS measurements. 
3.3.3. Optimization of crosslinking 
3.3.3.1. Type B GNPs 
Chemical crosslinking is a necessary step for the physicochemical stabilization of gelatin 
nanoparticles in aqueous environment. Hence, gelatin nanoparticles using gelatin B (bloom 
75) were crosslinked with varying concentrations of crosslinker (i.e., 
diisopropylcarbodiimide) for varying crosslinking time intervals in order to get stable 
nanoparticles. In this context, different parameters, e.g., concentration of crosslinker, 
crosslinking time and temperature of crosslinking reaction were investigated for their 
influence on particle size, size distribution and zeta potential. 
Varying crosslinker concentration 
The crosslinker, i.e., diisopropylcarbodiimide with different concentration range (0.99 mg/mL 
- 15 mg/mL) was added to the uncrosslinked suspension of GNPs to evaluate its impact on 
mean size and size distribution. The concentration of gelatin in the aqueous  phase was 20 
mg/mL, the volumteric ratio of water to acetone was 1:15, and the stabilizer, i.e., poloxamer 
188, was 3 % (w/v) [123].  
Varying crosslinking time 
To investigate the minimum crosslinking reaction time, the GNPs dispersion system was 
subjected  to react with the  crosslinker  at fixedfor  different crosslinking  time intervals (0.5 
h to 48 h). Other parameters, e.g., gelatin concentration in the aqueous phase (water) and 
poloxamer concentration in the organic phase (acetone) was kept constant, i.e., 20 mg/mL and  
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the  3 % (w/v), respectively. The crosslinking time was investigated for DIC concentration of 
5 mg/mL
 
and 15 mg/mL.  
Varying Temperature  
In addition to the optimization experiments regarding the concentration and crosslinking time 
of the crosslinker, the crosslinking of GNPs suspension was conducted  at different 
temperatures, i.e., room temperature, 30°C and 50°C. The effect of  temperature on the 
physicochemical stabilization of crosslinked GNPs was investigated employing DLS 
measurements of the crosslinked GNPs at different time points at given temperatures.  
3.3.3.2. Type A GNPs 
Varying crosslinking time  
The gelatin concentration in the solvent phase was 20 mg/mL, the solvent/non-solvent ratio 
was 1:15, and the stabilizer concentration was 3 % (w/v). Gelatin nanoparticles of type A with 
three blooms, i.e., bloom 90-100, bloom 175 and bloom 30 were prepared following the 
standard protocols of nanoprecipitation [123]. Subsequently, the nanosuspension was 
crosslinked with 0.347 mL taken from stock solution of DIC in acetone having concentration 
of 69.16 % [w/v]. The concentration of crosslinker in the nanosuspension was 15 mg/mL 
which was previously optimized for type B gelatin nanoparticles at room temperature. The 
gelatin A nanosuspension was allowed to react with the crosslinker in above amount for 
various crosslinking time with intermittent DLS measurements until a stable colloidal system 
is formed with lowest size distribution (PDI < 0.2) while measuring in water as a dispersion 
medium. Hence, the crosslinking time at which the PDI was less than 0.2 with an attenuator 
value between 6-9 was regarded as optimum crosslinking time.  
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Varying gelatin concentration 
Different concentrations of gelatin A of each bloom, i.e., 10, 20, 30 and 40 mg/mL in the 
solvent phase were used for particles preparation. The objective was to investigate the impact 
of gelatin concentration in the solvent phase on mean size and size distribution of DIC-
crosslinked GNPs. 
3.3.4. Nanoparticle characterization  
3.3.4.1. Determination of size and zeta potential  
The mean particle size and size distribution of DIC-crosslinked gelatin nanoparticles was 
measured after varying crosslinking times before purification. The mean size (Z-average 
mean) and surface charge (zeta potential) were evaluated  by dynamic light scattering (DLS) 
and laser Doppler anemometry, respectively using Zetasizer nano-ZS (Malvern instruments, 
Ltd., Worcestershire, UK). The samples were diluted 10 times with Milli-Q water before DLS 
measurements. Each sample was measured in triplicate for each formulation. 
3.3.4.2. Morphology of nanoparticles by scanning electron microscopy (SEM) 
Regarding the sample preparation for SEM visualization, these protocols were followed: a 
silicon wafer was placed on the top of a metal hub using carbon adhesive tape. Afterwards, a 
drop of TFF-washed nanosuspension was deposited onto the silicon wafer. Subsequently, 
samples were subjected to overnight drying for the evaporation of dispersion medium, i.e., 
water, under ambient conditions. Then, using a current of 20 mA, the samples were sputtered 
for 50 s with a gold layer of ~15 nm using sputter coater (Q150R ES, Quorum Technologies 
Ltd, East Grinstead, UK). Finally, SEM images were obtained using SEM (EVO HDI5, Carl 
Zeiss Microscopy, GmbH, Jena, Germany) with an acceleration voltage of 5 kV. 
.   
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3.3.5. Determination of crosslinking extent 
For the determination of % crosslinking extent of DIC-crosslinked gelatin nanoparticles, an 
already established quantification method known as trinitro-benzene sulfonic (TNBS) assay 
was employed [127]. This assay is a spectrophotometry-based determination of primary un-
crosslinked amino groups attached to epsilon () carbon atom of lysine amino acid residues of 
proteins. Briefly, the gelatin nanoparticles suspension (DIC-crosslinked and un-crosslinked) 
was firstly lyophilized. Next to lyophilisation, 10 mg gelatin nanoparticles from crosslinked 
and un-crosslinked were separately dispersed in 1 mL of sodium bicarbonate solution (4% ) 
and 1 mL of TNBS solution (0.5% w/v). The mixture was then heated at 40°C for 4 h. 
Afterwards, 3 mL of HCl (6 N) was added to it followed by autoclaving at 120°C using 1.03-
1.17 bar for 1h. The hydrolysed mass was diluted to 10 mL with Milli-Q water. Subsequently, 
ethyl acetate (5 mL) was added to this aqueous hydrolysate  to remove the un-reacted TNBS. 
Afterwards, 5 mL aliquot of the aqueous phase was diluted to 25 mL with Milli-Q water and 
the absorbance was checked at max = 349 nm using a UV-Vis spectrophotometer (Perkin-
Elmer Lambda35, Rodgau, Germany) against a blank.  
The blanks were prepared following the same procedure without the addition of gelatin. The 
number of primary amino groups was utilized as measure for crosslinking extent using the 
following equation (1).                    
 












L/mol.cm is the molar absorptivity of TNB-lys, b is the path length in cm, 
and x is the sample weight in grams.  
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3.3.6.  Measurement of un-reacted DIC 
A validated method of gas chromatography (Table 3-1) was employed for the quantification of 
un-reacted diisopropylcarbodiimide present in the GNPs suspension. For this purpose, gas 
chromatograph (GC) (Shimadzu GC-2010, Japan) connected with a flame ionization detector 
(FID) (Shimadzu GC-2010, Japan) was employed. The details of the validated GC method are 
given in Table 3-1.  




GC column Supreme-5 MS 
Length of column 25 m 
Packing material 5 % Phenylpolysilphenylensiloxane 
Flow rate 1.24 mL/min 
Injection mode Split, split ratio of 1:10 
Carriers gas Nitrogen/Air 
Oven temperature program 40°C for 5 minutes, rising temperature at 10°C/min followed by 
holding at 220°C for 5 minutes 
Detector Flame ionization detector (FID) 
 
The sample for GC analysis was prepared following these protocols. Briefly, the supernatant 
was isolated after centrifugation of DIC-crosslinked GNPs (24,000 g for 20 minutes). 
Afterwards, the supernatant was isolated and analyzed for the quantification of un-reacted 
DIC present in the GNPs dispersion using the aforementioned validated procedure of gas 
chromatography (Table 3-1). 
3.3.7. Measurement of diisopropylurea 
During crosslinking of GNPs with diisopropylcarbodiimide, diisopropylcarbodiimide is 
believed to be converted to its by-product, diisopropyl urea (DIU). Therefore, for the analysis 
of diisopropyl urea, proton NMR spectroscopy was exploited. For this purpose, 
1
H NMR 
spectra were recorded at 298 K in acetone-d6 with a Bruker Avance 500 spectrometer (Bruker, 
BioSpin GmbH, Rheinstetten, Germany) equipped with a 5 mm BBO probe. The chemical 
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shifts were represented in parts per million (ppm) relative to the acetone peak at δH 2.05. The 
1
H NMR spectra were taken with a sufficient number of scans, typically NS=128, to give an 
acceptable S/N, because the peaks of interest, the DIU methyl protons, were in the same range 
as those achieved for the carbon-13 satellites of the DIC methyl groups.  
3.3.8. Cytotoxicity evaluation 
The in-vitro cytotoxicity potential of DIC-crosslinked GNPs was evaluated using the 3-(4, 5-
dimethythiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay. MTT assay is the 
colorimetry-based determination of metabolically active cells after incubation of DIC-
crosslinked GNPs formulations with different particle concentrations for a proper incubation 
time (4 hours). The dye compound, MTT undergoes reduction by mitochondrial succinate 
dehydrogenase produced by viable cells converting to dark purple coloured formazan product. 
Subsequently, the product formazan is solubilized with DMSO and measured 
spectrophotometrically at a wavelength of 550 nm [128]. The reaction is illustrated in (Figure 
3-2). 
In the MTT assay adenocarcinoma human alveolar basal epithelium cells A549 were used. 
The cells were cultured in RPMI-1640 with 2 mM glutamine and 10 % FCS in sterile 96-well 
plates until a cell density of approximately 1× 10
4
 cells per well. 
 
 
Figure 3-2. Reaction of the tetrazolium salt MTT to formazan during the cell viability test 
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Cells were washed two times with HBSS buffer and incubated with 200 µL of a known 
concentration of DIC-crosslinked GNPs for 4 h in incubator at 37 °C with careful shaking. 
For the comparative evaluation, positive and a negative control were also included in the 
experiment. For a positive control the cells were treated with 2 % Triton X-100 which causes 
cell lysis due to the surface activity. For negative control, HBSS was used, to keep the cells in 
non-harmful conditions, so no cell death occurs during the incubation time (4 h). After 
incubating for 4 h, cells were washed again with 200 µL HBSS buffer followed by the 
addition of 200 µL of 10 % MTT reagent. The cells were then incubated for further 4 h at 37 
°C with careful shaking. After 4 h, they were again washed with HBSS buffer followed by the 
addition of 100 µL DMSO in each well to dissolve the product formazan. After the incubation 
time allowing for uptake of the tetrazolium salt and reduction to formazan the supernatant was 
removed. The formed formazan gives a deep purple colour which was measured at 550 nm 
with an Infinite
®
M200 plate reader (Tecan group Ltd., Männedorf, Switzerland). The 
percentage viability for DIC-crosslinked GNPs suspension with different nanoparticles 
concentrations was determined from positive and negative controls using the following 
equation (2).  
 Cell Viability [%] =
Absorption of sample−Absorption of positive control
Absorption of negative control−Absorption of positive control
× 100………...(2) 
3.4. Results and Discussion 
The current research work is focussed on introducing a novel strategy for the physicochemical 
and mechanical stabilization of gelatin nanoparticles, with the application of a zero-length 
apolar crosslinker, i.e., diisopropylcarbodiimide (DIC). According to our hypothesis, the 
apolar crosslinker due to its low polarity is believed to be confined in the organic phase, i.e., 
acetone (non-solvent phase for gelatin), hence might not diffuse into the hydrophilic core of 
GNPs. Therefore, only the amino and carboxylic functional groups on the colloidal interface 
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will get conjugated thus making an amide bond on the surface of nanoparticles. Gelatin 
nanoparticles were formulated according to the already established protocols of 
nanoprecipitation [123]. Briefly, the aqueous phase containing gelatin was added slowly in 
dropwise manner to the organic phase, i.e., acetone containing 3 % [w/v] poloxamer 188 as 
stabilizer) [129, 130]. Due to diffusion of solvent phase into non-solvent phase, a strong 
interfacial turbulence is produced which leads to precipitation of gelatin at the interface in the 
form of gelatin nanoparticles. After particles formation via nanoprecipitation, the apolar 
crosslinker, i.e., diisopropylcarbodiimide was added slowly in a dropwise manner to the 
GNPs suspension followed by stirring for varying time intervals to allow the formation of 
crosslinks in gelatin nanoparticles. The preparation methodology and proposed crosslinking 
mechanism is schematically shown in Figure 3-3.  
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Figure 3-3. (a) Schematic representation of the procedure to from GNPs via nanoprecipitation 
and crosslinking the particles by DIC. (b) Schematic representation of DIC-mediated 
crosslinking mechanism. Step 1: Formation of diisopropylcarbodiimide-mediated activation 
of (-COOH) to form an unstable intermediate O-Acylisourea. Step 2: Secondary reaction with 
nucleophilic substitution of free primary amino groups presented by lysine into the formerly 
formed DIC activated ester leading to formation amide crosslink at GNPs interface [131-137]. 
  
Formulation Optimization for the Design of Surface-Crosslinked Gelatin Nanoparticles 
39 
3.4.1. Optimization of crosslinking conditions 
3.4.1.1. Type B GNPs  
Optimization of crosslinker concentration 
Gelatin-B of bloom number 75 g was used in this experiment. Type B gelatin contains 
approximately 126 × 10
-5
 moles carboxylic acid groups/g on glutamic and aspartic acids and 
approximately 33 × 10
-5 
moles ε-amino groups/g on the lysine and hydroxy-lysine residues 
[138]. Due to the predominance of free carboxylic groups, type B gelatin possesses an acidic 
isoelectric point (IEP) of 4.5-5.5 [54, 139]. Due to its hydrophilicity, it readily dissolves in 
water. Therefore chemical crosslinking is indispensable for the physicochemical stabilization 
in water. In our case, the hydrophobic crosslinker (diisopropylcarbodiimide) activates the 
carboxylic functional groups present in the protein matrix of GNPs thus forming a transition 
unstable product called as O-acylisourea. This intermediate product readily reacts with a 
nucleophile, e.g., primary amino groups present in the gelatin polypeptide chains. This 
reaction leads to the formation of a stable amide bond which acts as a crosslink (Figure 3-3- 
(b)). The crosslinked GNPs after crosslinking with DIC in the concentration range 
(0.99 mg/mL to 3.98 mg/mL) have a mean size of 250 nm with an in-homogeneous size 
distribution (PDI > 0.2) (Figure 3-4). Further increase of DIC concentration ≥ 4.98 mg/mL, 
monodisperse nanosuspensions with PDI <0.2 were obtained while measuring in water. This 
is an indication that the particles are sufficiently crosslinked and are not getting dissolved in 
aqueous environment. The formulation can be considered as physicochemically stable. Larger 
crosslinker concentrations from 4.98 mg/mL – 15 mg/mL has no influence on the particle size 
(Figure 3-4). The physicochemical stability of crosslinked GNPs in aqueous environment can 
also be measured in terms of a physical parameter of the dynamic light scattering device 
(DLS) known as attenuator index. According to DLS measurements, attenuator index is a 
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DLS parameter which is dependent on nanoparticles’ concentration in a given sample. The 
higher the concentration of particles in a given sample, the lower will be the attenuator index 
and vice versa. There are 11 attenuator positions in the ZetaSizer ranging from 100% to 
0.0003% [140-142]. The relationship between the attenuator and the transmission value is 
shown in Table 3-2. The transmission value is the percentage of laser light that is transmitted 
through the sample cuvette. 
Table 3-2. Relationship between attenuator index and transmission value
 
[141] 






1 0.0003 7 1 
2 0.003 8 3 
3 0.01 9 10 
4 0.03 10 30 
5 0.1 11 100 
6 0.3   
 
The attenuator index of crosslinked GNPs formulations crosslinked with DIC concentration 
below 4.98 mg/mL is higher than 9 which is a clear indication for a low concentration of 
nanoparticles (see Table 3-3, Figure 3-4). It means that the nanoparticles cannot maintain their 
integrity in water and are getting dissolved on contact with aqueous environment. The 
attenuator index shifts to 8 using a crosslinker concentration above 4.98 mg/mL. At these 
concentrations of DIC, the nanoparticles maintain their particulate nature with PDI less than 
0.2 in aqueous environment (see Table 3-3 and Figure 3-4).  
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Figure 3-4. Effect of crosslinker concentration (DIC) on particle size and size distribution. 
The nanoparticles were measured in water after 10 times dilution before purification with 
three independent experiments (n = 3). 
 
Table 3-3. Mean size and size distribution of DIC-crosslinked GNPs crosslinked at different 
concentrations of crosslinker (DIC) at room temperature. (Crosslinking time: 24 - 48 h). 
A crosslinker concentration above 4.98 mg/mL has also no relevant impact on the mean size 
of the nanoparticles. This experiment was performed at crosslinking times of 24 - 48 h but 
crosslinking time was also found to have an impact on particle stabilization kinetics. 
Therefore, it is important to investigate the effect of crosslinking time on mean size and size 
distribution.  
DIC Concentration 
[mg / mL] 
Mean size [nm]  
± S.D. 
Mean PDI  
± S.D. 
Attenuator index 
0.99 382.00 ± 175.42 0.75  ± 0.12 11 
1.98 248.48  ± 13.53 0.58  ± 0.09 11 
2.98 237.98  ± 6.50 0.60  ± 0.05 11 
3.98 221.88  ± 38.36 0.38  ± 0.07 10 
4.98 241.80  ± 30.07 0.16* ± 0.08 8* 
5.96 237.18  ± 3.63 0.07* ± 0.02 8* 
7.95 243.33  ± 3.16 0.06* ± 0.03 8* 
8.94 248.28  ± 2.50 0.04* ± 0.02 8* 
9.93 241.78  ± 2.82 0.08* ± 0.04 8* 
15 268.40  ± 7.75 0.12* ± 0.03 8* 
* represents stabilized nanoparticles with PDI < 0.2 
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Optimum crosslinking time 
Effect of crosslinker concentration 
In this experiment, the minimum crosslinking time was studied for two concentrations of DIC, 
i.e., 5 mg/mL and 15 mg/mL at ambient temperature. The crosslinking under these conditions 
produced stable nanoparticles in aqueous environment with lowest size distribution (PDI < 
0.1) after 25 – 30 h at 5 mg/mL and 15 - 20 h at 15 mg/mL (see Figure 3-5). At these 
crosslinking times, the mean size of particles in water is between 230 - 250 nm with PDI less 
than 0.2. The physicochemical stability of crosslinked GNPs in aqueous environment at 
different time points can also be correlated to the corresponding attenuator index value of the 
measurements. As explained in section 3.4.1, that attenuator index value is dependent on 
nanoparticles concentration. The larger the value of attenuator index, the lower will be the 
particles concentration in a given sample volume and vice versa. The attenuator index range 
of 6 - 9 is a representation of enough concentration of sufficiently crosslinked, stable GNPs in 
the sample. The attenuator value > 9 is an indication of unstable or slowly dissolving GNPs 
system. The respective attenuator indices at different crosslinking times with corresponding 
mean sizes and PDIs are presented in Table 3-4. It was observed that the attenuator index 
range of 8 - 9 was achieved after crosslinking time of 15 h at crosslinker concentration of 15 
mg/mL while for crosslinker concentration of 5 mg/mL, the desired attenuator index (8 - 9) 
was achieved after crosslinking time of 25-28 h. The mean size of crosslinked GNPs at these 
conditions was observed to be 241.80 nm and 231.72 with PDI values of less than 0.2. Hence, 
increasing the crosslinker concentration to 15 mg/mL reduced the optimum crosslinking time 
(see Figure 3-5 and Table 3-4).  
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Figure 3-5. Mean size and size distribution analysis at different incubation times at room 
temperature (concentration of DIC in nanosuspension. (a) 5 mg/mL (b) 15 mg/mL). 
 
Table 3-4. Relationship between mean particle size, size distribution and attenuator index of 
ZetaSizer at two concentrations of DIC. The attenuator index range (6-9) is an indicator of 
enough concentration of stable crosslinked GNPs due to sufficient crosslinking. 
(a)
CT [h] Mean size [nm] ± S.D. (PDI), [Attenuator index] 
 CDIC [5 mg/mL] CDIC [15 mg/mL] 
1 188.31 ± 50.07 (0.65),[11] 95.83 ± 39.00 (0.66),[11] 
2 91.26 ± 115.57 (0.67),[11] 107.43 ± 56.84 (0.58),[10] 
5 121.41 ± 48.21(0.53),[11] 175.78 ± 34.07 (0.36),[10] 
10 128.20 ± 74.06 (0.55),[10] 211.28 ± 3.63 (0.26), [10] 
15 113.10 ± 28.37 (0.46),[10] 217.98 ± 3.50 (0.19),[9]* 
20 150.66 ± 41.96 (0.45),[10] 231.72 ± 4.29 (0.15),[9]* 
25 209.33 ± 50.20 (0.31),[9]* 242.76 ± 13.07 (0.16),[8]* 
28 242.66 ± 33.69 (0.18),[8]* 266.82 ± 10.30 (0.20),[8]* 
30 247.70 ± 14.16 (0.15),[8]* 268.22 ± 11.65 (0.12),[7]* 
48 236.98 ± 6.93 (0.11),[8]* 268.40 ± 11.24 (0.12),[7]* 
* represents stabilized nanoparticles with PDI <0.2; 
(a)
 CT: Crosslinking time 
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Effect of Temperature 
Since the rate of endothermic chemical reactions enhances with elevation in temperature, the 
crosslinking of GNPs with DIC with might also be activated. The crosslinking was carried out 
at three different temperatures, i.e., room temperature, 30°C and 50°C in an incubator keeping 
the concentration of DIC constant (i.e., 15 mg/mL). It was observed that the optimum 
crosslinking time is decreased with increase in temperature of the crosslinking mixture, 
demonstrating that rate of chemical crosslinking with DIC is enhanced at high temperatures. 
This behaviour was already expected. While performing the crosslinking of GNPs at room 
temperature, 30°C and 50°C, the optimum crosslinking time of GNPs at which the PDI was 
also observed to be less than 0.2 was 16 h, 2 h and 1 h, respectively as can be seen in Figure 
3-6 and Table 3-5. This means that the DIC-crosslinked GNPs after being crosslinked with 
these crosslinking times at respective temperatures possess sufficient colloidal stability in 
aqueous environments. Moreover, the phenomenon of acceleration of DIC-mediated 
stabilization kinetics with increasing temperature was also supported by the apparent drop in 
the attenuator values of each formulation in DLS measurements. As explained previously the 
attenuator value 6 - 9 is a representation of sufficient concentration of stable, crosslinked 
GNPs suspension in DLS measurements. In fact, the crosslinked gelatin nanoparticles have 
the tendency of undergoing dissolution on contact with water due to insufficient crosslinking 
and consequently, the attenuator value increases (> 9). In this experiment, while performing 
the crosslinking at room temperature, 30°C and 50°C, the crosslinked GNPs suspensions 
attain the attenuator value of 8 - 9 after 16 h, 2 h and 1 h, respectively as shown in Table 3-5.  
The mean particle sizes of GNPs crosslinked under these conditions are between 230 and 270 
nm and PDI less than 0.2. Hence, it can be inferred that temperature has a direct impact on 
DIC induced stabilization kinetics of GNPs. 
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Figure 3-6. Mean size and size distribution analysis at different crosslinking reaction times at 
room temperature, 30°C and 50°C for DIC concentration of 15 mg/mL.  
 
Table 3-5. Relationship between particle size and attenuator index of DLS machine for DIC 
concentration of 15 mg/mL at different crosslinking times at room temperature, 30°C and 
50°C. The attenuator index range (6-9) is an indicator of enough concentration of stably 
crosslinked GNPs in aqueous medium due to sufficient crosslinking. 
 
(a)
CT [h] Mean size [nm] ± S.D. (PDI), [Attenuator index] 
Room Temperature 30°C 50°C 
0.5 95.83 ± 50.07 (0.66), [11] 
 
146.83 ± 16.27 (0.49), [11] 
 
228.86 ± 16.27 (0.21), [10] 
 
1 107.43 ± 115.57 (0.58), [10] 
 
218.54  ± 6.44 (0.33), [10] 
 
248.43 ± 6.44 (0.17)*[9] 
 
2 175.78 ± 48.21 (0.36), [10] 
 
253.55  ± 9.21 (0.13)*[9] 
 
269.45 ± 9.21 (0.16)*[8] 
 
3 211.28 ± 74.06 (0.26), [10] 
 
246.61  ± 6.66 (0.10)*[8] 
 
283.41 ± 6.66 (0.11)*[7] 
 
5 217.98 ± 28.37 (0.19), [10] 
 
240.93  ± 22.29 (0.09)*[7] 
 
262.31 ± 22.29 (0.06 )*[7] 
 
16 231.72 ± 41.96 (0.15)* [8] 
 
271.33  ± 4.77 (0.12)*[7] 
 
254.47 ± 4.77 (0.06)*[7] 
 
22 242.76 ± 50.19 (0.16)*[8] 227.30  ± 11.82 (0.08)*[7] 
 
256.31 ± 11.82 (0.05)*[7] 
 
* represents stabilized nanoparticles with PDI < 0.2; 
(a)
 CT: Crosslinking time 
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In summary, with increasing the concentration of crosslinker and temperature of crosslinking 
mixture, the optimum crosslinking time at which the DIC-crosslinked GNPs possess the 
lowest PDI in aqueous environment, is reduced. The summary of crosslinking times at 
different crosslinker concentrations and temperature is summarized in Table 3-6. 
Table 3-6. Summary of the optimum crosslinking times of DIC-crosslinked GNPs at different 














5 Room temperature 48 241.80 ± 30.07 0.16 ± 0.08 8 
5 30 25 252.92 ± 16.80 0.14 ± 0.05 8 
5 50 5 250.54 ± 11.53 0.11 ± 0.07 8 
15 Room temperature 20 231.72 ± 4.29 0.15 ± 0.02 8 
15 30 2 253.55 ± 9.21 0.13 ± 0.02 8 
15 50 1 269.45 ± 9.21 0.16 ± 0.03 8 
*Crosslinking time at which PDI is <0.2; **AI:  Attenuator index; 
(a)
 Concentration of DIC 
3.4.1.2. Type A GNPs  
The formulation development of surface-crosslinked gelatin A nanoparticles was also in focus 
in this chapter due to some special advantages of type A gelatin. Due to its high isoelectric 
point (IEP of 7 - 9), type A gelatin exists as a cationic polymer at neutral pH [19, 139]. 
Therefore, GNPs fabricated from type A gelatin would have cationic surface at neutral pH (7). 
Due to this cationic character, it can be exploited as a delivery vehicle for negatively charged 
hydrophilic macromolecules which includes nucleic acid-based macromolecules, e.g., 
oligonucleotides, plasmid DNA, locked nucleic acid nucleotide and small interfering RNA 
[98] as well as peptide-based drugs with isoelectric points (IEP < 7). The cationic surface is 
also advantageous in context of higher uptake rates for positively charged nanoparticles than 
negatively charged particles [143]. Accordingly, a larger in vitro uptake has been 
demonstrated for cationic gelatin A NPs in comparison to negatively charged gelatin B 
nanoparticles [143]. A good in vitro safety profile of gelatin A NPs has already been reported 
[144]. In contrast, in order to get positively charged gelatin particles, sometimes cytotoxic 
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cationic agents, e.g., PEI, have also been employed [98, 145]. Hence, the GNPs fabricated 
from type A gelatin would be a promising delivery system in the context of enhanced cellular 
uptake avoiding the surface cationization procedures while using toxic poly-cations by 
covalent attachment to the surface of GNPs.    
Optimum crosslinking time 
Since, the isoelectric point of type A is between 7 and 9 [139] it is intrinsically a cationic 
molecule at neutral pH. This high isoelectric point of type A gelatin is attributed to a high 
density of free amino groups offered by basic amino acids (e.g., L-lysine, hydroxylysine, 
asparagine and glutamine) as compared to acidic amino acids.  
Just like gelatin B nanoparticles, the nanoparticles fabricated from gelatin A are not able to 
maintain their particulate nature in aqueous environments without crosslinking, therefore 
crosslinking is indispensable to make them physicochemically stable in aqueous 
environments. Using the zero-length hydrophobic crosslinker (DIC) renders a stable solid 
structure to the particles. Due to the difference of isoelectric points between the two types of 
gelatin, the DIC-mediated stabilization kinetics using gelatin A was also found to be different 
from gelatin B. 
Together with the crosslinking time for particles stabilization the effect of molecular weight or 
better the bloom number was studied. Bloom number of gelatin is proportional to its mean 
molecular mass. It is an indication of the strength of a gel formed from a solution of known 
concentration. The bloom number is defined as the force (weight) required to depress a given 
sample area of gel a distance of 4 mm. The higher the bloom number, the stronger the gel 
strength. The relationship between bloom number & average molecular mass is given in the 
following Table 3-7. 
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Table 3-7. Relationship between bloom number and molecular mass [139]. 
Bloom Number Average molecular mass (Dalton) 
50-125 (Low Bloom) 20,000-25,000 
175-225 (Medium Bloom) 40,000-50,000 
225-325 (High Bloom) 50,000-100,000 
Therefore, we conducted a crosslinking of type A GNPs with the three blooms mentioned 
above with DIC for different crosslinking times with parallel measurements using DLS to 
check the impact on mean size of so produced nanoparticles. The concentration of DIC used 
was 15 mg/mL which was optimized for gelatin B GNPs as was discussed in section 3.4.1.1. 
As evident from DLS measurements in Table 3-8, the stabilization kinetics of GNPs produced 
from type A with different blooms is different using a constant gelatin concentration in solvent 
phase (20 mg/mL) and crosslinking with a constant concentration of crosslinker (DIC), i.e., 15 
mg/mL. It was observed that crosslinked GNPs prepared from gelatin type A bloom 90-100 
and 300 attain a mean size of 400 - 500 nm and PDIs below 0.2 when measuring after 
crosslinking for 144 h in water. After long crosslinking times (144 h), the particles possess the 
lowest PDI in water. The colloidal stability was also characterized in terms of the attenuator 
value displayed by DLS measurements as explained in section 3.4.1. The attenuator index >10 
indicates low particle concentrations present in a given sample volume. In the case of gelatin 
nanoparticles, it can be assumed that due to insufficient crosslinking the particles have the 
tendency to get dissolved in water, consequently converting the sample into gelatin solution. 
Hence, the solution state of GNPs would exhibit high attenuator index (>9). The attenuator 
value from 6 – 9 generally represents enough concentration of stable, crosslinked GNPs in 
water In the above example, attenuator 9 is achieved after crosslinking time of 144 h for 
bloom 90 and 300 (see Table 3-8). At this crosslinking time, the PDI was also found to be 
below 0.2. Hence, the optimum crosslinking time for gelatin A for both bloom 90 and 300 at 
room temperature is regarded as 144 h. On the other hand, the GNPs produced from gelatin A 
(bloom 175) attains mean size 300 - 350 nm with PDI less than 0.2 after crosslinking the 
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dispersion for approximately 48 h. The GNPs dispersion system crosslinked for 
approximately 48 h possess already colloidal stability in water also depicted by low attenuator 
value (value of 9 after 48 h crosslinking). Therefore, the minimum crosslinking time needed 
for stabilization in aqueous media for gelatin A (bloom 175) is 48 h at room temperature (see 
Table 3-8).  
After comparing the optimum crosslinking times of type A GNPs (bloom 90, 175 and 300) 
with type B GNPs (bloom 75) (see Table 3-4), it is clear that GNPs fabricated from gelatin B 
are crosslinked faster as compared to GNPs fabricated from gelatin A. The possible reason for 
this variability may be the difference of amino acid composition and isoelectric points of both 
types of gelatin. Type B gelatin has 100 - 115 millimoles of free carboxylic groups per 100 g 
of protein and an isoelectric point (IEP) of 4.7 - 5.2 [139]. On the other hand type A gelatin 
contains 78 - 80 millimoles of free carboxylic groups per 100 g of protein and an isoelectric 
point of 7 - 9 [139, 146]. Thus, the relative proportion of free carboxylic groups found in 
gelatin B is higher than gelatin A. So, this different distribution of acidic and basic functional 
groups  in two types of gelatin might be a driving force for the variability of DIC-based 
crosslinking kinetics of the two gelatin types. As it was explained in section 3.4 (Figure 3-3) 
that the crosslinker (DIC) activates the free (un-bonded) carboxylic groups which is an 
initiation step in the crosslinking process. Since, gelatin B offers more free carboxylic groups 
for the formation of crosslinks, the particles get stabilized faster. In contrast, gelatin A 
contains comparatively low proportion of free carboxylates, and hence the crosslinking 
process mediated by DIC will be slower. This could explain the variability of crosslinking 
kinetics of both types of gelatin.  
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Table 3-8. Relationship between mean particle size/size distribution of DIC-crosslinked type 
A GNPs of different blooms and attenuator index. The crosslinker concentration was 15 
mg/mL at room temperature. The attenuator indices (6-9) is an indicator enough nanoparticles 





Mean size [nm] ± S.D. (PDI), [Attenuator index] 
Type A (bloom 90-110) Type A (bloom 175) Type A (bloom 300) 
0.5 134.78 ± 51.68 (0.3), [11] 105.47 ± 31.50 (0.33), [11] 101.55 ± 52.11 (0.29), [11] 
1 116.46 ± 34.64 (0.32), [11] 85.98 ± 36.30 (0.57), [11] 85.81 ± 36.26 (0.21), [11] 
2 122.80 ± 44.55 (0.31), [11] 97.86 ± 18.71 (0.88), [11] 57.95 ± 6.28 (0.28), [11] 
4 174.39 ± 106.86 (0.39), [11] 332.72 ± 61.06 (0.72), [11] 276.11 ± 279.55 (0.5), [11] 
8 114.54 ±16.97 (0.35), [11] 381.97 ± 48.48 (0.58), [10] 82.01 ± 24.45 (0.32), [11] 
16 384.75 ± 68.60 (0.52), [11] 357.53 ± 39.22 (0.2), [10] 174.64 ± 98.96 (0.94), 11] 
48 484.03 ± 35.91 (0.26), [11] 321.80 ± 28.79 (0.05), [9]* 486.10 ± 15.41 (0.36), [11] 
96 479.20 ± 3.55 (0.24), [9] 334.94 ± 8.13 (0.09), [8]* 483.65 ± 62.34 (0.26), [10] 
144 479.73 ± 15.56 (0.11), [8]* 317.27 ± 4.68 (0.05), [7]* 501.23 ± 5.87 (0.14), [9]* 
* represents stabilized nanoparticles with PDI < 0.2, CT
a
: crosslinking time 
 
Effect of gelatin concentration 
After optimization of crosslinking time for gelatin A nanoparticles of different blooms at a 
constant concentration of diisopropylcarbodiimide, i.e., 15 mg/mL, it was necessary to study 
the effect of gelatin concentration in the solvent phase on the mean size and size distribution 
of nanoparticles. The DIC-crosslinked particles were measured both in acetone as well as 
water as dispersion media. For comparison of DLS measurements, the measurements in 
acetone were considered which are presented in Figure 3-7 and Table 3-9. It was observed that 
the mean size of nanoparticles slightly increases with increasing the gelatin concentration 
from 10 mg/mL to 20 mg/mL in the solvent phase for all blooms. With further increase in 
gelatin concentration up to 30 mg/mL, the mean size of particles also increases significantly. 
The mean size was increased around 210 nm, 252 and 264 nm for bloom 90 - 110, bloom 175 
and bloom 300 respectively (Figure 3-7 and Table 3-9). 
Formulation Optimization for the Design of Surface-Crosslinked Gelatin Nanoparticles 
51 
 
Figure 3-7. Effect of gelatin concentration on mean size and polydispersity index of GNPs. 
The samples were measured in triplicates for three independent experiments. Acetone was 
used as dispersion medium and samples were diluted 10 times with acetone before DLS 
measurements. Statistics (N.S: statistically non-significant on the basis of p > 0.05 as per one-
way ANOVA). * statistically significant p ˂ 0.05 as per one-way ANOVA. 
However, using concentrations above 30 mg/mL almost for all studied blooms resulted in 
visible bigger precipitates formation of gelatin which cannot be re-dispersed easily (Table 
3-9). The phenomenon of increase in mean hydrodynamic diameter and visible precipitates 
formation (phase separation) can be attributed to an increase in viscosity with increasing 
gelatin concentration in the solvent phase. The higher the viscosity of the solvent phase due to 
higher polymer concentration the lower would be the rate of diffusion of the solvent towards 
the non-solvent [99, 147]. Consequently, the bigger would be the particle sizes of so produced 
GNPs. In fact, there is always an optimum polymer concentration range in the solvent phase 
for particles formation, beyond which there is irreversible polymer aggregation leading to 
phase separation. So, for type A GNPs, the maximum permissible gelatin concentration for 
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optimum particles formation was observed to be 30 mg/mL. These observations are in close 
agreement with the results of other investigators regarding other polymers [147, 148]. 
Table 3-9. Effect of gelatin type, bloom number and concentration on particle size and size 
distribution. All samples were measured in acetone as dispersion medium before particles 




Mean size ± SD [nm] (PDI) 
Type A (bloom 90-110 g) Type A (bloom 175 g) Type-A (bloom 300 g) 
10 171.88 ± 11.73 (0.09) 183.61 ± 7.19 (0.09) 192.37 ± 12.91(0.07) 
20 188.78 ± 12.08 (0.07) 191.10 ± 23.08 (0.09) 199.38 ± 2.78 (0.08) 










: Not determined due to formation of bigger visible precipitates 
After measuring the same samples in water as a dispersion medium before purification, it was 
observed that using gelatin concentration of 10 mg/mL in the solvent phase, the mean sizes of 
GNPs of all blooms were almost similar. The mean size of crosslinked GNPs for all blooms 
was in the range of 200 - 300 nm. With increasing gelatin concentration to 20 mg/mL, the 
mean size of GNPs produced by bloom 90 and 175 is increased up to 300 nm and 330 nm 
respectively, with PDIs below 0.2. The mean size of gelatin A (bloom 300) is increased up to 
400 nm using a gelatin concentration of 20 mg/mL. Increasing the gelatin concentration 
further to 30 mg/mL, the mean size of GNPs produced from gelatin A bloom 90 and bloom 
175 possess a mean size in the range 348 - 367 nm with PDI lower than 0.2. For gelatin A 
(bloom 300) in concentration of 30 mg/mL, the mean size is increased up to approximately 
530 nm with PDI less than 0.2 (see Table 3-10).  
 
 
Formulation Optimization for the Design of Surface-Crosslinked Gelatin Nanoparticles 
53 
Table 3-10. Effect of gelatin type, bloom number and concentration on mean particle size and 
size distribution. All samples were measured in water as dispersion medium before particles 




Mean size ± SD [nm] (PDI) 
Type A (bloom 90-110 g) Type A (bloom 175 g) Type-A (bloom 300 g) 
10 242.43 ± 28.32 (0.09) 233.10 ± 35.31(0.09) 240.28 ± 12.57 (0.28) 
20 329.50 ± 17.82 (0.05) 303.28 ± 7.30 (0.18) 414.18 ± 3.83 (0.24) 










: Not determined due to formation of bigger visible precipitates 
 
In summary, the mean size of DIC-crosslinked GNPs increases with increasing the bloom 
number and concentration of gelatin in the solvent phase. The increase in hydrodynamic 
diameter can be attributed to high viscosity of gelatin solution in the solvent phase. The 
molecular weight of gelatin is a direct function of bloom number of gelatin used as shown in 
Table 3-7. The larger the bloom number of the gelatin used, the higher will be the molecular 
weight. In turn, the viscosity of gelatin solution increases with increasing the bloom number. 
Therefore, the higher the bloom number of gelatin used, the higher the viscosity of the solvent 
phase (i.e., aqueous solution of gelatin) and the lower will be the diffusion rate of the solvent 
phase to the non-solvent phase during nanoprecipitation. This retardation of diffusion of 
solvent phase results in the formation of bigger particles. 
It was also observed that the mean hydrodynamic diameter of particles while using water as a 
dispersion medium is higher than the sizes measured in acetone as can be seen in Figure 3-8, 
Table 3-9 and Table 3-10. This can be attributed to swelling of the crosslinked gelatin 
nanoparticles which behaves as a nano-hydrogel system following dispersion in aqueous 
media. 
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Figure 3-8. Comparison between mean sizes of DIC-crosslinked gelatin A NPs measured in 
acetone and water as dispersion media. *p < 0.05: statistically significant according to paired 
two-tailed t-test.   
3.4.2. Investigation of crosslinking  
3.4.2.1. Determination of crosslinking degree – TNBS Assay 
The crosslinking degree of diisopropylcarbodiimide-mediated crosslinked gelatin 
nanoparticles was quantified using the already established protocols of trinitro 
benzenesulphonic acid (TNBS) assay [127]. This assay is a spectrophotometry based 
determination of primary amino groups in both crosslinked and un-crosslinked gelatin 
nanoparticles.From the absorbance values of both un-crosslinked and crosslinked gelatin 
nanoparticles, the  numbers of un-crosslinked primary amino groups in crosslinked gelatin 
nanoparticles were calculated using the equation mentioned in section 3.3.5. It was observed 
that % crosslinking extent of gelatin nanoparticles increases with increasing the crosslinker 
concentration until an equilibrium crosslinking or plateau is obtained (see Figure 3-9). It can 
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be seen that the  plateau is achieved around 3.98 mg/mL. Further increase in crosslinker 
concentration (>3.98 mg/mL) has no influence on crosslinking extent of GNPs. It is also 
evident from the  statistical analysis (One-Way ANOVA) that the respective crosslinking 
extent for crosslinker concentrations from 3.98 mg/mL up to 18.4 mg/mL were non-
significant statistically. Therefore, increasing the concentration of crosslinker above 3.98 
mg/mL does not affect the % crosslinking extent of GNPs. This supports the idea of 
crosslinking saturation. It can also be speculated that the crosslinker (DIC) has no access to 
more free primary amino groups which are assumed to be present in the core of particles. 
 
Figure 3-9. Relationship between % crosslinking extent and concentrations of crosslinker 
(DIC) for 18 h crosslinking reaction time. The volumes were kept constant during the 
preparations. Values determined from TNBS assay by using the absorption maximum of 
max
 
= 349 nm, n = 3. Statistics (N.S: Non-significant statistically on the basis of p > 0.05 as 
per one-way ANOVA). * Statistically significant p ˂ 0.05 as per one-way ANOVA. 
 
To investigate the influence of crosslinking time on crosslinking extent, crosslinking of GNPs 
was performed at 48 h and the crosslinking extent was calculated (Figure 3-10). It was 
observed that increasing the crosslinking time from 18 h to 48 has no significant impact on % 
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crosslinking degree. After statistical evaluation of data (one-way ANOVA, p ˃ 0.05), it can be 
inferred that the corresponding crosslinking extents at respective DIC concentrations were 
statistically not significant. Therefore, increasing the crosslinking time of above 18 h, the 
crosslinking degree is not affected no matter how much concentration of DIC is used. The 
highest crosslinking extent achieved was ~25 - 30 %. This low crosslinking extent might be 
correlated with the hydrophobicity of diisopropylcarbodiimide. Due to the hydrophobic nature 
of DIC, the accessibility of the crosslinker into the aqueous core is very limited. Therefore, it 
can be assumed that the un-crosslinked amino groups should be located in the core of the 
nanoparticles which have no exposure with the crosslinker. Consequently, the core of the 
particles is free from the crosslinker. This idea is supported by the DLS measurements as 
discussed previously, which demonstrated that the crosslinked particles are physicochemically 
stable in aqueous environments. If the interface of the GNPs is not crosslinked, the un-
crosslinked core would get dissolved in water thus forming no particulates. 
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Figure 3-10. Relationship between % crosslinking degree and concentration of crosslinker for 
48 h crosslinking reaction time. Values determined by TNBS assay using an absorption 
maximum of λmax = 349 nm, n = 3. Statistics (NS: Non-significant on the basis of p > 0.05 as 
per one-way ANOVA). 
On the basis of results extracted from TNBS assay we can construct a hypothesized model of 
DIC surface crosslinked GNPs. This model is called as surface-crosslinked GNPs which is 
characterized by an un-crosslinked core surrounded by a crosslinked outer layer (see Figure 
3-11). This model is based on the assumption that the crosslinked functional groups are 
located on the outside while the un-crosslinked functional groups are located in the interior of 
GNPs. Moreover, based on the principal that all crosslinkable groups are homogeneously 
distributed throughout the GNPs matrix, a core-shell GNP sphere is the possible structure 
which can explain this model. This core-shell structure is composed of an inner sphere of 
approximately 111 nm radius surrounded by a crosslinked edge of approximately 14 nm (see 
Figure 3-11).  
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Figure 3-11. Proposed hypothetical model of DIC-crosslinked GNP based on TNBS assay. V 
(sphere): Total volume of GNP sphere. V (internal sphere): Volume of non-crosslinked sphere, V 
(crosslinked): Volume of crosslinked part of GNP, R (un-crosslinked sphere): Radius of uncross linked 
part of GNP which is the interior of GNP. R (sphere): Total radius of GNP. D (crosslinked): 
Thickness of the crosslinked edge (nm). 
3.4.2.2. Monitoring of crosslinking 
Measurement of un-reacted DIC 
The crosslinker (DIC) which remains unreacted during crosslinking was quantified employing 
gas chromatography (GC) method connected with flame ionization detector (GC-FID). Prior 
to analysis of actual samples of DIC-crosslinked GNPs, calibration curve was made after 
plotting peak areas under each GC chromatogram versus corresponding standard 
concentrations of diisopropylcarbodiimide in acetone. For this study, three different 
formulations of GNPs with different amounts of crosslinker were analyzed. Briefly, these 
GNPs suspensions were centrifuged at 20,000 × g for 25 minutes. The supernatant was 
isolated and analyzed for the amount of un-reacted DIC present in each formulation. 
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Table 3-11. Relationship between crosslinker amounts (mg) used initially for crosslinking and 
amounts of DIC consumed in crosslinking of GNPs 
Mass of DIC used for 
crosslinking (mg) 
Un-reacted mass of DIC (mg) 
± SD 
Reacted mass of DIC
 a
 (mg) ± 
SD 
32.4 26.36 ± 3.03 6.04 ± 3.03 
48.6 44.40 ± 0.21 4.20 ± 0.21 
64.8 57.38 ± 0.01 6.97 ± 0.01 
a: 
The reacted amounts were found statistically insignificant on the basis of p > 0.05 as per one-way ANOVA 
From the data in Table 3-11, we can conclude that the converted amounts  of DIC are similar 
regardless of whatever amount of crosslinker being used for crosslinking. As the gelatin 
concentration and thus the particles concentration is more or less the same, this behaviour is 
complementary to the TNBS assay results. The summary is that the amount of DIC in the 
crosslinking process is extremely low. Furthermore, specific amount of crosslinker is 
participating in the crosslinking of GNPs irrespective of the initial amount of DIC used. This 
is an indication that the crosslinking process is saturable (see Table 3-11). It can inferred, the 
crosslinker (DIC) due to its hydrophobicity has only access to the functional groups which are 
present at the GNPs interface. Therefore, the crosslinking process ceases when all the 
functional groups present on the colloidal interface are conjugated. 
Measurement of diisopropylurea  
It is already explained in section 3.4 (Figure 3-3) b) of this chapter, that 
diisopropylcarbodiimide covalently couples the carboxylic acid groups with the primary 
amino groups which are present in the GNPs peptidal matrix. This leads to the formation of 
amide bond which acts as a crosslink. These crosslinks are the foundations of 
physicochemical and mechanical stability gelatin nanoparticles in hydrophilic media. As a 
result, DIC is converted into its  side-product which is called as  diisopropylurea (DIU) that is 
soluble in organic solvents, e.g., acetone. For the qualitative and quantitative analysis of DIU, 
1
H-NMR spectroscopy was employed. For the quantification of DIU in the GNPs 
N.S. 
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nanosuspension, the supernatant was analyzed using proton NMR spectrometer. For this 
purpose, DIC-crosslinked GNPs suspension was centrifuged (24,000 × g, for 30 minutes), and 
so isolating the supernatant and discarding the pellet. Subsequently, the supernatant was was 
analyzed using 
1
H- NMR spectroscopy. 
The proton NMR spectrum of the crosslinking mixtures showed resonances for DIC together 
with tiny signals for the by-product DIU providing the methyl resonances for quantification 
(Figure 3-12 A). In contrast to DIC, the methyl protons of DIU were slightly shifted to higher 
field appearing almost free of superimposition in the region of the high field carbon-13 
satellite of the DIC methyl resonances (Figure 3-12 A, close-up). Therefore, integration of the 
separate DIU methyl doublet lines as well as the DIC methyl carbon-13 satellite lines could 
easily be performed (Figure 3-12 B). These integration values were taken to establish the 
relationship between the amount of DIC and DIU, taken into account that a carbon-13 satellite 
resonance represented only 0.55 % of the complete peak intensity. This way of quantification 
provided much more accurate results than a direct integration of the methyl resonances of the 
main compound DIC. The following equation (4) can be employed to calculate the % DIU 





∫ 𝐷𝐼𝑈 (𝑚𝑒𝑡ℎ𝑦𝑙 𝑟𝑒𝑠𝑜𝑛𝑎𝑛𝑐𝑒)
∫ 𝐷𝐼𝐶 ℎ𝑖𝑔ℎ 𝑓𝑖𝑒𝑙𝑑 𝑠𝑎𝑡𝑒𝑙𝑖𝑡𝑒 𝑠𝑖𝑔𝑛𝑎𝑙 (𝑚𝑒𝑡ℎ𝑦𝑙 𝑟𝑒𝑠𝑜𝑛𝑎𝑛𝑐𝑒)
0.55%
× 100 ………………………….....................(4) 
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*DIC methyl carbon-13 satellites 
Figure 3-12. Quantification of the reaction by-product (DIU). (A) 
1
H-NMR-spectrum of the 
supernatant of the crosslinked GNPs. The close-up in green shows the spectrum of the 
supernatant between 1.00 and 1.06 ppm; in red the signal of DIU methyl protons and in blue 
the high field satellite peak of DIC. (B) Shows the integration of the DIU methyl resonances 
and of the DIC methyl carbon-13 satellites. 
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It is evident from the calculated % relative amounts of DIU measured for each formulation 
using 
1
H NMR spectroscopy (Figure 3-13), that a very low amount of by-product is obtained 
during the crosslinking of GNPs with diisopropylcarbodiimide. It is also clear that using a 
fixed mass of gelatin (20 mg), the % relative amount of DIU formed during crosslinking is not 
dependent on initial amount of DIC being used for crosslinking of GNPs. In summary, it is 
evident from NMR and GC based measurements that only a certain number of amino and 
carboxylic functional groups are participating in the crosslinking process of GNPs which is 
not increasing with increasing the initial amount of crosslinking. Moreover, after comparing 
these results with TNBS experiments, it can also be concluded that the GNPs are crosslinked 
to a very low extent using DIC. 
 
Figure 3-13. Quantification of the reaction by-product DIU. The diagram shows the results of 
the DIU quantification, calculated by the integral of the corresponding peaks for different 
amounts of crosslinker. Negative control: sample without gelatin. Statistics (* p ˂0.05 as per 
one-way ANOVA, N.S: Non-significant statistically) 
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In summary, the TNBS assay, gas chromatography and 
1
H NMR spectroscopy support the 
hypothesis of surface crosslinking. Presumably, this is due to the access of crosslinker to a 
certain number of amino and carboxylic groups which are present in the colloidal interface of 
GNPs. While, the diffusion of the crosslinker (DIC) into the hydrophilic core of GNPs is very 
limited or restricted. 
3.4.3.   Zeta potential of DIC-crosslinked GNPs 
The zeta potential of DIC induced-crosslinked gelatin nanoparticles was determined at pH range 
of 6-10. Due to the fact that gelatin is a poly-ampholyte biopolymer, it contains both cationic 
and anionic functionalities. Therefore, the net charge of gelatin is dependent on the pH of 
nanosuspension. Since gelatin-B contains high amount of acidic functional groups (e.g., free 
carboxylates), therefore it possess an acidic isoelectric point (IEP) of 4.7 - 5.4 [146, 149]. 
Hence, it can be expected that the GNPs formulated from type B gelatin should have neutral 
surface charge at pH 4.7 - 5.4 while it should be negative at pH above the 5.4 provided that 
the isoelectric point is not being altered during crosslinking of gelatin. On the other hand, type 
A gelatin is basic biopolymer possessing an isoelectric point of 7 - 9 [139, 150]. Therefore, it 
can be expected that gelatin A nanoparticles should be positively charged at pH below its 
isoelectric point (pH 7 - 9) and negatively charged at pH >9 provided that the isoelectric point 
is not being altered during crosslinking of GNPs. The pH dependent zeta potential profile for 
both types of gelatin can be theoretically represented as shown in Figure 3-14. 
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Figure 3-14. Theoretical scheme of pH dependent surface charge of type A and Type B GNPs. 
After measuring the zeta potential of DIC-crosslinked GNPs, it is clear (see Figure 3-15) that 
the zeta potential of gelatin B nanoparticles is slightly positive (~ between +7 and +11 mV) at 
pH 5 (isoelectric point of type B gelatin). The surface charge becomes negative at pH ≥ 7. The 
zeta potential approaches to zero at pH range of 6-7. It means that the isoelectric point of 
gelatin B is increasing up to a value of 6 and 7 as can be seen in Figure 3-15. 
Likewise, type A GNPs possesses positive zeta potential (approximately +20 mV) at its 
isoelectric point, i.e, pH 7 - 9. The zeta potential approaches to zero around pH 9.5, hence a 
slight shifting of IEP towards 9.5. Therefore, it can be inferred that there is slight increase of 
isoelectric points in both gelatin A as well as gelatin B nanoparticles following crosslinking 
with diisopropylcarbodiimide. 
Looking at the amino acid composition of gelatin B, it contains 2.7% L-lysine and 5% 
arginine [151]. Assuming that all lysine residues are engaged in the crosslinking leaving 
behind 5% arginine residues which are un-crosslinked. The pKa value of arginine (12.1) [152] 
is higher than the pKa value of L-lysine (10.3). Due to the consumption of acidic groups 
(carbonic acid groups having pKa value of ~ 4) due to crosslinking, the isoelectric point is 
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shifted to a high pH value (~6.5-7) as can be seen in Figure 3-15 due to the predominance of 
basic amino acids. 
 
Figure 3-15. Zeta potential of type A and type B GNPs crosslinked with DIC [15 mg/mL] 
measured at different pH values. 
Similarly, the isoelectric point of type A gelatin shifts to pH ~ 9.5. Due to this shift of 
isoelectric point to higher pH value, the zeta potential of type A GNPs is positive at its native 
IEP (i.e., pH 7-9) due to the presence of predominantly protonated amino groups on the 
surface of GNPs.  
3.4.4.   Morphology of nanoparticles – Scanning Electron Microscopy  
The visualization of DIC-induced crosslinked GNPs using scanning electron microscopy 
(SEM) revealed that they have spherical morphology (Figure 3-16). The mean sizes of 
particles were also calculated from SEM image using image J
®
 (see Table 3-12). It can be 
observed that the mean size calculated from SEM image is lower than the corresponding 
mean size measured on DLS. Possibly, this can attributed to drying of dispersion medium 
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(water) from GNPs droplets before SEM analysis. On the other hand, the particles in aqueous 
dispersion also include the solvent while measuring the mean diameter which is known as the 
hydrodynamic diameter in DLS measurements. The same observation has also been reported 
by other investigators [98, 153]. 
Table 3-12. Size characterization of DIC crosslinked Type-B GNPs purified via tangential 
flow filtration (TFF) 
Formulation 
name 
Mode of purification Size ± S.D. [nm] 
     DLS









filtration____________                                 
(RC
c
 membrane of 100 
kDa) 
224.5 ± 1.87 
(0.12) 
145.33 ± 58.12 
a) 
terms in parenthesis represent polydispersity index. 
b)
100 particles analysed using 
image J software. RC
c
: Regenerated cellulose, TFF
d
: Tangential flow filtration 
  
 
Figure 3-16. SEM images of DIC-crosslinked type B GNPs washed via tangential flow 
filtration (TFF) set-up containing modified regenerated cellulose membrane (Hydrosart) of 
100 kDa pore size. (a) concentrated sample. (b) Diluted sample 
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3.4.5. Cytotoxicity Evaluation 
In order to evaluate the cytotoxicity of DIC-crosslinked GNPs, MTT assay was used. MTT 
test was performed on four different concentrations of gelatin nanoparticles. The results show 
no significant cytotoxicity on adenocarcinoma human alveolar basal epithelium cells (A549) 
incubated with gelatin nanoparticles for 4 hours ( Figure 3-17). Thus, it can be concluded that 
the DIC-crosslinked nanoparticles are biocompatible and do not possess any pronounced in 
vitro toxicity up to 1 mg/mL GNP. Although, the crosslinker diisopropylcarbodiimide (DIC) 
possesses certain biological toxicity profile, the GNPs crosslinked with DIC show no 
significant in vitro cytotoxicity on A549 cells. The crosslinking of GNPs with DIC involves 
the formation of only intra-and intermolecular amide or ester bonds which are being 
established within the gelatin molecules. These newly established amide bonds caused by DIC 
works as crosslinks. Besides this crosslinking, the crosslinked does not induce any noticeable 
toxicity in the gelatin matrix. The DIC is converted to its by product, known as 
diisopropylurea (DIU) which is efficiently removed during the purification process. For a 
more generalized statement more different cell lines need to be investigated. 
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Figure 3-17. Cell viability analysis of DIC-crosslinked GNPs by MTT assay after 4 h 
incubation on A549 cells. The % viability for all concentrations of GNPs is above 80 %. MTT 
assay was performed in triplicates and data is average of three independent experiments. 
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3.5. Conclusions 
This research work is focused on efforts to stabilize gelatin nanoparticles after selectively 
crosslinking the colloidal interface of GNPs produced from both type B and type A gelatin 
using hydrophobic zero length crosslinker, i.e., diisopropylcarbodiimide (DIC). Crosslinking 
of GNPs produced as a result of nanoprecipitation resulted in the formation of GNPs of 200 - 
300 nm using type B gelatin and 300 - 500 using type A gelatin. The physicochemical stability 
of crosslinked gelatin nanoparticles in aqueous medium was highly dependent on optimum 
crosslinker concentration, crosslinking time and temperature of crosslinking mixture. The 
surface crosslinking phenomenon was supported by saturation of crosslinking degree and the 
limited utilization of crosslinker during crosslinking reaction. The crosslinking degree of 
particles increased proportionally with increasing crosslinker concentration until an 
equilibrium crosslinking degree was achieved (approximately 25 - 30 %) which was not 
affected further by increasing the crosslinker concentration and crosslinking time. This 
showed a saturation of the crosslinking process. Assuming a homogenous distribution of 
primary amino groups within the GNPs matrix, it can be speculated that DIC exhibits 
reactivity with 25 - 30 % amino groups which are located at the GNPs interface. The rest of 
70-75 % amino groups are believed to be located in the core of GNPs which are still un-
crosslinked. The morphology of these surface crosslinked gelatin nanoparticles indicates 
spherical geometry as confirmed by SEM analysis. No cytotoxicity was observed on A549 
cell lines. Therefore, it can be concluded that the apolar zero length crosslinker (DIC) only 
crosslinks the colloidal interface of GNPs dispersed in acetone. These DIC-surface 
crosslinked gelatin nanomaterials provide a new nanotechnology-based platform thus 
providing an excellent biodegradable and biocompatible delivery system for hydrophilic 
macromolecules especially for protein-based APIs.  












4 Optimization of Purification Procedures for Surface-







Parts of this chapter have been published in: 
 
Abdul Baseer, Aljoscha Koenneke, Joseph Zapp, Saeed A. Khan, Marc Schneider, Design 
and Characterization of Surface Crosslinked Gelatin Nanoparticles for the Delivery of 
Hydrophilic Macromolecular Drugs. Macromolecular Chemistry and Physics. 2019. 220(18): p. 
1900260. 
  
Optimization of Purification Procedures for Surface-Crosslinked Gelatin Nanoparticles 
71 
4.1. Abstract  
This chapter is focused on comparative evaluation of different techniques employed for the 
purification of diisopropylcarbodiimide-induced surface-crosslinked gelatin nanoparticles. 
These methods include centrifugation, dialysis and crossflow filtration. In this chapter, the 
purification efficiency of the two purification techniques, i.e. dialysis and tangential flow 
filtration in terms of removing excess stabilizer (poloxamer 188), un-reacted crosslinker and 
its by-product from the crude crosslinked GNPs suspension was investigated. Moreover, the 
effect of certain critical process parameters, e.g., membrane type, pore size of membrane and 
amount of washing water used on the purification performance and physicochemical 
properties of nanoparticles were evaluated. According to this comparative evaluation, the 
tangential flow filtration was found to be comparatively efficient and straightforward method 
than dialysis and centrifugation. 
  
Optimization of Purification Procedures for Surface-Crosslinked Gelatin Nanoparticles 
72 
4.2. Introduction 
As discussed in detail in chapter 1 (section 1.5.1.1), gelatin nanoparticles can be prepared 
using different formulation techniques. During particles’ formulation there are certain 
formulation additives and side products whose removal from the nanoparticles suspensions is 
indispensable. These additives and side products include the excess amounts of stabilizers, 
polymerizations initiators, chemical crosslinkers and their by-products, etc. In general, 
different approaches have been reported for the purification of polymeric nanoparticles to get 
rid of these impurities. These include micro-filtration [154, 155], centrifugation and 
ultracentrifugation [154, 156, 157], gel-filtration [158], dialysis [159], diafiltration [160, 161] 
and cross-flow microfiltration [154, 162]. The most commonly used approaches are 
centrifugation and ultracentrifugation which are comparatively advantageous in removing 
large quantities of impurities from the crude nanosuspensions [163, 164]. Although, 
centrifugation is a simple, straightforward and highly reported purification approach, it has 
some serious demerits. Amongst these demerits, the centrifugation at high speed sometimes 
produces hard pellets of nanoparticles which are very difficult to re-disperse in water [165]. 
The problem of re-dispersibility becomes more pronounced when organic solvents, e.g., 
acetone and alcohol are used as dispersion media [99]. In order to avoid this problem, low 
speed centrifugation is used but this leads to a significant loss of nanoparticles and 
consequently low yield of nanoparticles. While using dialysis as a purification tool, it results 
in the release of drug loaded in nanoparticle due to lengthy duration of operation. While using 
size exclusion chromatography (SEC), very low amounts of nanoparticles can be processed. 
During formulation of DIC-crosslinked gelatin nanoparticles following nanoprecipitation, 
there are certain undesired hazardous substances present in the final crude nanosuspension 
system. These include excessive amounts of stabilizers such as poloxamer 188, the un-reacted 
crosslinker (DIC) and its by-product, i.e., diisopropylurea (DIU). To remove these impurities 
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from the crude nanosuspensions, an effective purification methodology of nanoparticles is 
highly demanding. 
In our application, while employing the centrifugation as a purification tool, the surface-
crosslinked nano-formualtion consisting of DIC-crosslinked GNPs also suffer from non-
redispersibility. The pellet obtained after centrifugation cannot be re-dispersed in water 
despite vigorous mechanical shaking. Even, application of ultra-sonication assisted sheer 
stress did not solve the problem of re-dispersibility. 
Therefore, in order to avoid the formation of non-dispersible pellet and loss of particles, we 
attempted to use tangential flow filtration (TFF) and dialysis membrane filtration as a 
purification tools for washing of these DIC-mediated surface-crosslinked gelatin 
nanoparticles. 
In the work discussed in this chapter, we optimized the tangential flow filtration for the 
purification of DIC-crosslinked gelatin nanoparticles. For comparative evaluation, the 
particles were also purified using low speed centrifugation and dialysis. For the assessment of 
purification performance of TFF and dialysis-based purification, the residual amounts of 
poloxamer 188, unreacted crosslinker and its by-product in the final product were determined 
employing cobalt-thiocyanate colorimetric assay, gas chromatography (GC) and 
1
H-NMR 
spectroscopy, respectively. The ultra-filtration (TFF, dialysis) and centrifugation-based 
purified surface-crosslinked gelatin nanoparticles (scGNPs) were characterized in terms of 
mean size and size distribution using dynamic light scattering. For morphological 
characterization of purified GNPs, scanning electron microscopy (SEM) was used. 
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4.3. Experimental  
4.3.1. Materials  
Gelatin B bloom75 from bovine skin, was obtained from Sigma-Aldrich, Munich, Germany. 
Acetone was obtained from VWR-International, Darmstadt, Germany. Tangential flow 
filtration (TFF) cassettes (Vivaflow 50 R) fitted with modified regenerated cellulose material 
(hydrosart) with a pore size of 30 kDa and 100 kDa were purchased from Sartorius Stedim 
Biotech Ltd., Goettingen. Another TFF setup (Minimate
TM
 TFF capsule) with a pore size of 
300 kDa, composed of polyethersulfone was purchased from VWR international Ltd., 
Darmstadt, Germany. Dialysis membranes (spectra/por7 flat trial kit having flat width of 28 
mm, diameter of 18 mm, volume of 2.5 mL/min) composed of regenerated cellulose was 
purchased from Spectrum Laboratories, Europe B.V., Breda, Netherland). Milli-Q water with 
a resistivity of 18.2 MΩ⋅cm was used throughout the experiments. 
4.3.2. Preparation of DIC-crosslinked gelatin nanoparticles 
The DIC-crosslinked gelatin nanoparticles were prepared following the standard protocols 
mentioned in chapter 3, section 3.3.2. 
4.3.3. Purification of DIC-crosslinked GNPs 
For the purification of crude nanosuspension, the purification tools, i.e., centrifugation, 
dialysis and cross-flow filtration were employed and evaluated in terms of removal 
effectiveness from impurities, i.e., the stabilizer (poloxamer), the crosslinker (DIC) and its 
side product, diisopropylurea (DIU). 
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4.3.3.1. Centrifugation   
Since, high speed centrifugation leads to formation of hard pellet of NPs which cannot be re-
dispersed in water, the DIC-surface linked GNPs suspension system was purified with three 
different sets of centrifugation conditions followed by re-dispersion in water. The 
centrifugation conditions included a speed of 3000×g for 10 minutes, 5000×g for 15 minutes, 
3000×g for 25 minutes and speed of 3000×g for 30 minutes. The crude nanosuspensions were 
purified with one time centrifugation. 
4.3.3.2. Dialysis 
The dialysis membrane composed of regenerated cellulose (RC) with a pore size of 50 kDa 
was employed for purification. Regenerated cellulose was used because of its compatibility to 
a wide range of organic solvents including acetone. In our application scenario, as all the 
impurities of the crude dispersion system are soluble in acetone, hence dialysis was performed 
in acetone as a dialysate reservoir for 24 h. The dialysate was re-freshed after 1 h, 2h and 24 
h. For dialysis experiment, a sample volume of 16 mL crude nanosuspension was filled in pre-
washed regenerated cellulose membrane tube of 5 cm in length. Afterwards, the dialysis tube 
filled with crude nanosuspension was immersed in 600 mL acetone as a dialysate reservoir. 
The dialysis process was continued for 24 h sufficient time to completely remove all the 
impurities from the nanosuspension. 
4.3.3.3. Tangential flow filtration (TFF) 
Two types of TFF assemblies with different membranes types and pore size were employed. 





 300 kDa, VWR international Ltd., Darmstadt, Germany) were used for the 
purification of DIC-crosslinked GNPs crude suspension. The membranes with three molecular 
weight cut-offs, i.e., 30, 100 and 300 kDa were used. The construction material of vivaflow 
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50 R was modified regenerated cellulose which is also known as hydrosart. According to 
specifications of manufacturer (Sartorius), the material, hydrosart, demonstrates highest 
degree of resistance to organic solvents. Another TFF device, i.e., Minimate
TM
 TFF capsule 
fitted with polyethersulfone (PES) membrane having pore size of 300 kDa was also 
employed. Since, the material PES is not completely compatible to acetone, therefore, the 
nanosuspension containing acetone as a main dispersion medium was diluted 10 times with 
water before starting TFF operation. With acetone concentration less than 10 % v/v, PES 
membrane showed compatibility. In terms of compatibility, the TFF device used here is not 
100 % compatible to acetone. Some parts of the device, e.g., the casing and tubings are 
composed of polycarbonate and nylon, respectively, which are not compatible to acetone. For 
this purpose, prior to starting TFF based washing, the crude nanosuspension was diluted with 
sufficient water to make the fraction of acetone below 10 % (v/v) for making the device 
components acetone compatible.  
The purification of crude nanodispersion using TFF involves passing the formulation parallel 
to the membrane surface (see Figure 4-1 a). The crude nano-suspension is then divided into 
two streams. One stream known as filtrate or permeate is composed of impurities having 
molecular weights smaller than the pore size of membrane. The other part known as retentate 
is the washed nanoparticles which is retained and re-circulated back into the initial container 
holding the crude nanosuspension. The working principal of TFF based purification of 
surface-crosslinked gelatin nanoparticles is shown schematically in Figure 4-1 (b). 
 




Figure 4-1. Schematic representation of TFF assembly used for the purification of sc-GNPs. 
(a). External overview of TFF assembly. (adapted from product operational manual provided 
by Sartorius) (b). Scheme of the working principal of TFF assembly.  
4.3.4. Evaluation of purification performance 
The purification efficiency of dialysis and TFF-based ultra-filtration was evaluated in terms of 
% clearance of stabilizer (Poloxamer P-188), unreacted crosslinker (DIC) and its by-product 
(DIU) from the DIC-crosslinked gelatin nanosuspension.  
4.3.4.1. Quantification of poloxamer 
For the quantification of poloxamer-188, a colorimetric assay known as cobalt thiocyanate 
method was used [166-168]. This assay is based on the formation of a water insoluble 
complex between poloxamer molecules and a dye known as cobalt thiocyanate. For the 
solubilization of this water insoluble complex, acetone was used, and subsequently quantified 
spectrophotometrically using 624 nm as the absorption maximum. The poloxamer content in 
the samples is proportional to poloxamer–complex formation. Briefly, the cobalt thiocyanate 
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solution was made after dissolving 3 g of cobalt (II) nitrate and 20 g of ammonium 
thiocyanate in Milli-Q water (100mL). Afterwards 1 mL from cobalt-thiocyanate solution was 
transferred to 10 mL falcon tube. To this solution, 2 mL of poloxamer solution and 2 mL of 
ethyl acetate was added followed by vigorous mixing. After mixing, the mixture was 
centrifuged (Thermo Fisher Scientific, Osterode am Harz, Germany) at 1000 × g for 5 
minutes [168]. After centrifugation, the poloxamer-cobalt complex was sedimented and the 
upper two layers formed by aqueous solution and ethyl acetate was discarded. The sedimented 
pellet was washed with 2 mL ethyl acetate followed by re-centrifugation at 1000 × g or 5 
minutes. The centrifugation and redispersion in ethyl acetate was repeated several times till 
the upper layer consisting of ethyl acetate solution became colourless. After washing 
thoroughly with ethyl acetate, 10 mL of acetone was added to the falcon tube followed by 
vigorous mixing until the pellet was completely dissolved in acetone. The calibration as well 
as the unknown samples (supernatants of GNPs formulation) were prepared in the same way. 
The absorbance at 624 nm was recorded using UV-Vis Spectrophotometer (Perkin-Elmer 
Lambda 35, Rodgau, Germany) against a blank. Calibration curve was constructed based on 
the above mentioned colorimetric assay. In order to quantify the poloxamer present in the 
TFF-based washed suspension containing surface-crosslinked GNPs, the suspension was 
centrifuged at 20000 × g for 20 minutes. The supernatant was extracted and analysed for the 
amounts of poloxamer using the calibration curve based on the cobalt thiocyanate assay and 
subsequently, the corresponding amounts of poloxamer present in the supernatants of dialysis 
and TFF washed crosslinked GNPs were calculated. For the quantification of residual 
amounts poloxamers in dialyzed samples, the acetone of the extracted supernatant was 
evaporated at room temperature and reconstituted with similar amount of Milli-Q water and 
then following the same procedure as was discussed for TFF washed samples. 
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4.3.4.2. Quantification of un-reacted crosslinker (DIC)  
For the measurement of residual amounts of DIC in the purified nanosuspension, the 
lyophilized DIC-crosslinked GNPs were re-dispersed in acetone to re-dissolve the residues of 
DIC if present in the purified nanoparticles. The dispersion was then centrifuged at 20,000 × g 
for 20 min. The supernatant was withdrawn for the quantification of residues of DIC using the 
validated gas chromatography method (Shimadzu GC-2010, Japan) connected with flame 
ionization detector (FID) (Shimadzu GC-2010, Japan). The procedure of gas chromatography-
based quantification has been described in chapter 3 (section 3.3.6). Briefly, Supreme 5-MS 
column with a length of 25 mm and inner diameter (ID) of 0.25 mm was used which 
contained 5% phenylpolysilphenlyensiloxane as a packing material with a film thickness of 
0.25 µm. The carrier gas used was a mixture of nitrogen and air. The flow rate of carrier gas 
was 1.24 mL/min. The injection mode selected was split with a split ratio of 1:10. The total 
run time was 28 minutes. During the elution process, the temperature of column oven was 
raised up to 40°C followed by warming to 220°C with a heating rate of 10°C/min. The 
temperature of 220°C was hold for 5 minutes. For the detection and quantification of DIC, 
flame ionization detector (FID) was used. 
For the quantification of DIC, a calibration curve was constructed by plotting the 
corresponding peak areas in the GC chromatograms versus different DIC concentration 
(mg/mL) in acetone. 
4.3.4.3. Quantification of crosslinking by product (DIU) 
For the measurements of traces of by-products (DIU) present in the purified GNPs, the 
lyophilized GNPs samples were dispersed in deuterated acetone (NMR grade acetone) to re-
dissolve the residual DIU if present in the washed gelatin nanoparticles. Subsequently, the 
suspension was centrifuged at 20,000 × g for 20 minutes. The supernatant was isolated for 
quantification of traces of DIU present in the dialysis/TFF washed nanoparticles using 
1
H-
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NMR spectroscopy. For this purpose, 
1
H-NMR spectra were recorded at 298 K in acetone-d6 
with a Bruker Avance 500 spectrometer (Bruker, BioSpin GmbH, Rheinstetten, Germany) 
equipped with a 5 mm BBO probe. The chemical shifts were reported in parts per million 
(ppm) relative to the solvent peak at δH 2.05.  
4.3.4.4. Fourier Transform-Infrared (FT-IR) analysis of crosslinked GNPs 
As explained in the mechanism of DIC-based crosslinking of gelatin nanoparticulates (see 
chapter 3, section 3.4.1) that DIC establishes amide bonds within the gelatin molecules, and is 
itself transformed into diisopropylurea. Nevertheless, for the experimental confirmation that 
the crosslinker (DIC) does not become a part of gelatin molecule during crosslinking reaction, 
the lyophilized samples of TFF-washed GNPs being crosslinked with different amounts of 
DIC were analysed using Fourier transform infrared spectrometer (FT-IR spectrometer 
(Tensor 27, Bruker, Ettlingen, Germany). The FT-IR spectra were recorded in transmittance 
mode over a wavenumber range of 400-5000 cm
-1
. Each spectrum was the accumulation of 32 
scans. The software used was OPUS V4. 
4.3.5. Measurement of particle size  
The size (z-average mean) and size distribution of centrifugation, TFF and dialysis-based 
washed surface crosslinked gelatin nanoparticles was analysed using dynamic light scattering 
using a Zetasizer nano-ZS (Malvern Instruments Ltd., Worcestershire, UK). The nanoparticles 
suspension was 10 times diluted with Milli-Q water at 25°C before measurement. Each 
sample was analysed in triplicates for three independent experiments. 
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4.3.6. Morphological Characterization 
4.3.6.1. Scanning Electron Microscopy (SEM) 
For SEM imaging, a drop of 20 µL of purified nanosuspension was dropped onto a silicon 
wafer already mounted on a metal hub using carbon adhesive tape. Afterward, the samples 
were allowed to dry overnight by evaporation at room temperature. Before SEM imaging, 
samples were coated with gold layer of approximately 15 nm, in an atmosphere of argon 
using sputter coater Q150 RES (Quorum Technologies Ltd. Laughton, UK). SEM images 
were recorded using EVO HDI5 microscope (Carl Zeiss Microimaging, GmbH, Jena, 
Germany).  
4.4. Results and Discussion  
After the production of nanoparticles, a crucial step is the purification of nanoparticles from 
the undesired impurities. The subsequent characterization of nanoparticles, e.g., the in vitro 
and in vivo evaluation and imaging, e.g., SEM, SPM and TEM measurements are mostly 
conducted with washed nanoparticles. In this context, numerous methods have been reported 
for the purification of nanoparticles. These include centrifugation, ultra-centrifugation, 
dialysis, tangential flow filtration, etc. The nanoparticles are necessarily purified from 
impurities such as the un-reacted crosslinker, its by-products and excessive amounts of 
stabilizers. Centrifugation is the most commonly used method for the purification of 
polymeric nanoparticles. However, when the particles are dispersed in organic solvents (e.g., 
acetone, alcohol etc.,), then centrifugation at higher speeds leads to formation of strong pellets 
which are not easily re-dispersible in water [99]. On the other hand, centrifugation at a low 
speed results in low nanoparticles yield. 
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In our scenario, the DIC-crosslinked GNPs cannot be purified with centrifugation-based 
washing due to the formation of non-dispersible pellet. Therefore, it was necessary to use 
alternative purification methods. 
In this context, we optimized the ultra-filtration in tangential flow filtration (TFF) mode for 
the purification of DIC-induced gelatin nanoparticles. The effect of different pore sizes of 
membrane and its possible impact on purification performance and the physicochemical 
properties of nanoparticles will be investigated to get a highly purified and stable nano-
formulation of DIC surface crosslinked GNPs. 
4.4.1. Nanoparticles preparation 
The formation of gelatin nanoparticles (GNPs) was carried out following the standard 
formulation as described in chapter 3 section 3.4.1.  
4.4.2. Optimization of purification 
4.4.2.1. Centrifugation 
After getting DIC-induced crosslinked GNPs suspension, it was purified with centrifugation 
followed by re-dispersion in water. The centrifugation was carried out at different speed and 
time. The mean size and size distribution of purified gelatin nanoparticles corresponding to 
each parameter is shown in Table 4-1. The DLS measurements indicate that increasing the 
speed of centrifugation and time, the mean size is also increased. Besides, the nano-dispersion 
is also showing in-homogeneous distribution at high centrifugation speeds and longer times of 
centrifugation. This is because the GNPs are converted to a strong pellet which is very 
difficult to re-disperse in water. 
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Table 4-1. Effect of centrifugation speed and time on mean size and size distribution. (*) 
Particles were centrifuged once. 
S.No. Time [min] *Centrifugation speed (× g) Mean size [nm] ± 
S.D.  
PDI ± S.D. 
1 10 3000 277.58 ± 0.14 0.18 ± 0.06 
2 15 5000 307.20 ± 11.93 0.27 ± 0.03 
3 25 3000 310.23 ± 11.70 0.24 ± 0.01 
4 30 3000 277.19 ± 7.15 0.26 ± 0.03 
 
So, the appropriate centrifugation speed and time at which the pellet can be re-dispersed in 
water is 3000 x g for 10 minutes. These nanoparticles possess the desired characteristics in 
terms of particle size (200 - 300 nm with PDI less than 0.2). But using centrifugation-based 
purification has two demerits. Firstly, the lower centrifugation speed leads to significant loss 
of particles (the data regarding the yield is not shown). Secondly, the particles cannot be 
purified completely from the impurities using one time centrifugation. So, in order to get 
stable nanoparticles with desired mean size and PDI with maximum particles recovery, it is 
necessary to purify the DIC-crosslinked GNPs suspension using alternate methods of 
purification.  
4.4.2.2. Dialysis and cross-flow filtration 
In order to by-pass the formation of non-redispersible pellet, dialysis and tangential flow 
filtration fitted with ultra-filtration membranes of different pore sizes were employed. The 
selection of membrane type and pore size was based on compatibility with acetone and 
molecular weights of impurities which need to be removed from the GNPs suspension. The 
physicochemical properties of these impurities are summarized in Table 4-2. For the effective 
removal of unwanted impurities as listed in Table 4-2 from the nanosuspension, the selected 
pore sizes of membrane used, i.e., 30, 50, 100 and 300 kDa are bigger than the molecular 
weights of impurities listed in Table 4-2. 
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Table 4-2. Impurities of DIC crosslinked GNPs 
Impurities Molecular weight 
(g/mol) 
Solubility 
Poloxamer 188 8400 Soluble both in water and acetone 
Diisopropylcarbodiimide 126.20 Soluble in acetone and water 
insoluble 
Diisopropylurea 144.22 Soluble in acetone and water 
insoluble 
4.4.3. Evaluation of purification performance 
4.4.3.1. Removal of Poloxamer-188  
The pore size of filtration membrane and amount of washing water used was found to be the 
rate limiting factors in purification efficiency in removing the poloxamer 188 having the 
molecular weight of ~ 8400 g/mol from the crude suspension of scGNPs. After quantitative 
determination of poloxamer 188 concentrations in the supernatant of dialyzed as well as TFF 
washed nanoparticles, it was observed that the purification efficiency is high while using 
higher pore size ultra-filtration membrane. The purification efficiency was expressed as % 
removal of poloxamer 188 from the nanosuspension (see Figure 4-2 a). The maximum pore 
size suitable for removal of poloxamer was found to be 300 kDa. Similarly, the amount of 
water in the washing cycle results in enhanced permeation of poloxamer across the membrane 
(see Figure 4-2 b). Therefore, the rate limiting factor of purification efficiency is both pore 
size of ultra-filtration membrane (maximum pore size of 300 kDa) and water utilization 
(> 2000 mL for a volume of 16 mL crude nanosuspension). 
The pore size of dialysis membrane was smaller than the pore size of TFF membrane, and the 
comparison of purification efficiencies of the two purification methodologies using 
membranes of different pore sizes is not rational. But, the main disadvantage of dialysis-based 
purification is the non-flexibility of exchange of dispersion medium, i.e., the dialysis cannot 
be performed in water as a dialysate if the crosslinked GNPs are dispersed in acetone. While 
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using water as a dialysate for purifying the particles dispersed in acetone, it leads to an 
extensive agglomeration of particles inside the dialysis bag which cannot be re-dispersed. 
Secondly, the dialysis cannot be performed in water due to the insolubility of crosslinker 
(DIC) and its by product in water. Due to these demerits, dialysis is not a good choice for the 
purification.  
 
Figure 4-2. Purification efficiency of TFF and dialysis-based purification in terms of % 
clearance of poloxamer and effect of critical parameters. (a) Effect of membrane pore size, 
and (b) effect of water amounts used in re-circulation using 100 kDa membrane using TFF 
based purification. 
 
Optimization of Purification Procedures for Surface-Crosslinked Gelatin Nanoparticles 
86 
4.4.3.2. Removal of un-reacted crosslinker (DIC) 
After analysis of supernatant of redispersed lyophilized GNP in acetone using a validated gas 
chromatography method, it was observed that the un-reacted crosslinker can be effectively 
removed from the suspension to approximately 100 % after purification with both dialysis (50 
kDa pore size) for 24 h and TFF filtration (pore size of 100 kDa and 300 kDa) for 8 h. There 
is no peak for any residual amount of DIC observed in the gas chromatogram of dialysis- and 
TFF-purified samples (see the GC chromatograms of washed samples in Figure 4-3). 
 
Figure 4-3. GC chromatograms. (a). DIC-crosslinked GNPs washed with dialysis. (b) 
Reference compound of DIC. (c). DIC-crosslinked GNPs washed with TFF filtration. 
4.4.3.3. Removal of crosslinking by product (DIU) 
For the detection and quantification of the by-product i.e., diisopropylurea (DIU) in the 
dialysis and TFF purified samples, the supernatant of both dialysis and TFF washed 
crosslinked GNPs was isolated after centrifugation at 20,000 × g for 20 min. In 
1
H-NMR 
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spectra of supernatant, no NMR signals corresponding to DIU were observed in the mixture 
(see Figure 4-4 for the 
1
H NMR spectra of washed NPs).  
 
 
Figure 4-4. Proton NMR (
1
H-NMR) spectra of supernatant of washed nanoparticles taken in 
deuterated acetone. (a) 
1
H-NMR spectrum of standard compound of DIU. (b) 
1
H-NMR 
spectrum of TFF purified scGNPs samples. (c) 
1
H-NMR spectrum of dialysis washed scGNPs 
sample.  
4.4.3.4. Fourier Transform-Infrared (FT-IR) analysis of crosslinked GNPs 
The FT-IR spectrum of native gelatin is characterized in terms of 5 types of infra-red (IR) 
absorption bands, known as amide bands. These are 5 sub-types of amide bands which are 
termed as amide A, amide B, amide I, II and III. The corresponding IR frequencies and 
functional groups representing these amide bands are elaborated in Table 4-3. FTIR spectra 
taken for both un-cross-linked as well as cross-linked gelatin are almost superimposed on 
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each other indicating that no structural change is induced by the crosslinker (see Figure 4-5). 
Besides, there is no significant change in the position of already present absorption bands. 
Table 4-3. IR absorptions bands of gelatin and corresponding vibrational frequencies and 
functional groups 
IR band Wavenumber (cm
-1
) Functional group 
Amide-A 3200-3400 N-H stretching 
Amide-B 2800-3100 C-H stretching 
Amide I 1660-1600 C=O stretching 
Amide II 1565-1500 C-N stretching 
and N-H bending 
Amide III 1240 C-N stretching 
 
 
Moreover, the FTIR spectra also demonstrated that no additional peak for the crosslinker DIC 
and its degradation product (diisopropylurea) was observed which reveals that DIC does not 
become a part of the peptidal structure of gelatin. It is clear from the crosslinking 
mechanistics explained in section 3.4.1, that the DIC conjugates only the free carboxlic and 
free amino groups constituting amide bond which acts as a crosslink which stabilizes the 
gelatin nanoparticles. Due to these stabilization bonds, the DIC-crosslinked gelatin do not 
dissolve in aqueous environments. 
In summary, the stabilizer (poloxamer), the un-reacted crosslinker (DIC) and its by-product 
(DIU) are efficiently removed from the nanosuspension using TFF based purification as 
compared to dialysis, as explained in Table 4-4.  
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Figure 4-5. FT-IR spectra of GNPs crosslinked with different amounts of crosslinker (DIC) 
purified with tangential flow filtration.   
 
Table 4-4. Comparison of TFF and dialysis in terms of removal of poloxamer 188, DIC and 
DIU from crude nanosuspension of DIC-crosslinked GNPs. 





Poloxamer -188 58.10 ± 12 98.3 ± 0.56 
Diisopropylcarbodiimide (DIC) 100 100 
Diisopropylurea (DIU) 100 100 
a
50 kDa pore size; 
b
100 kDa pore size  
 
4.4.4. Measurement of particle size and size distribution 
4.4.4.1. Effect of membrane type and pore size 
All TFF and dialysis-based washed samples of DIC-crosslinked GNPs possess nearly the 
same size and size distribution irrespective of membrane type and its pore size. All the 
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samples are statistically insignificant (according to one-way ANOVA, p > 0.05). There is no 
significant impact of pore size on the physicochemical properties of DIC-crosslinked gelatin 
nanoparticles as can be seen in Figure 4-6. 
 
Figure 4-6. Mean size and size distribution of DIC-crosslinked GNPs purified with dialysis 
and TFF-based purification, using membranes of different pore sizes and type (RC: 
regenerated cellulose; PES: polyethersulfone). Statistics: N.S: statistically non-significant on 
the basis of p > 0.05 as per one-way ANOVA 
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4.4.4.2. Effect of amount of water in re-circulation 
During TFF washing of crude nanosuspension, different amounts of water were recirculated 
across the TFF membrane. After the DLS measurements of nanoparticles washed with 
different amounts of water, it was observed that the size and size distribution was not 
changed. The mean size was always between 241 - 250 nm with PDI lower than 0.2 (See  
Figure 4-7).  
 
Figure 4-7. Particle size & size distribution versus volume of water used for TFF washing. 
Statistics: N.S: statistically non-significant on the basis of p > 0.05 using one-way ANOVA. 
4.4.5. Morphological Characterization 
4.4.5.1. Scanning Electron Microscopy (SEM) 
The SEM analysis of DIC-crosslinked GNPs revealed that the nanoparticles have spherical 
morphology (Figure 4-8). The mean size calculated from SEM image using image J® is 
summarized in Table 4-5. As can be seen that the mean size of gelatin nanoparticles calculated 
from SEM image is lower than that of DLS analysis. Presumably, this is due to drying of 
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samples before SEM imaging. On the other hand, the particles in aqueous dispersion are 
associated with a water shell which is termed as hydrodynamic radii in DLS measurements. 
The same observation has also been reported by other investigators [113, 130]. 
Table 4-5. Size characterization of DIC-crosslinked GNPs purified via different purification 
techniques 
S.No Mode of purification 
1
Mean size DLS 
(PDI) 
2
Geometric mean size 
(SEM) 
1 Centrifugation (3000 ×g for 
10 minutes) 
277.58 ± 14 (0.18) 125.25 ± 16.30 
2 Dialysis membrane filtration 
(50 kDa pore size) 
211.87 ± 31.71 
(0.12) 
166.97 ± 52.85  
3 Tangential flow filtration 
(100 kDa pore size) 
224.5 ± 1.87 (0.12) 145.33 ± 58.12 
1
terms in parenthesis represent polydispersity index. 
2




Figure 4-8. SEM micrographs of GNPs suspension purified with different techniques (a) DIC-
crosslinked GNPs purified with centrifugation (3000 × g; t = 10 min), (b) DIC-crosslinked 
GNPs purified with dialysis (regenerated cellulose membrane of 50 kDa), (c) DIC-crosslinked 
GNPs purified with tangential flow filtration (membrane 100 kDa pore size, concentrated 
sample), (d) same formulation with diluted sample.  
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4.5. Conclusions 
This research work demonstrated the possibility of tangential flow filtration for the 
purification of DIC surface-crosslinked gelatin nanoparticles which was proven to be 
comparatively more effective and efficient than dialysis and centrifugation having a couple of 
advantages. It was found to be effective in terms of removing the hazardous substances of 
formulation, i.e., the un-reacted crosslinker (DIC) and its by product diisopropyl urea (DIU) 
and excess amounts of stabilizer (poloxamer 188). The parameters influencing the purification 
efficiency of the TFF-based purification were membrane pore size and amount of water 
consumed in re-circulation cycles during washing treatment. The molecular weight cut-off 
range 100 - 300 kDa of TFF membrane was promising in removing these impurities 
effectively. Likewise, increasing the amount of water in re-circulation cycles enhances the 
purification efficiency. The physicochemical properties of purified crosslinked nanoparticles, 
e.g., mean size, size distribution and morphology of gelatin nanoparticles are not affected 
using a pore size of 100 kDa irrespective of whatever amount of water is being used for the 
purification. The mean particle size of purified nanoparticles was found to be between 200 - 
300 nm with PDI less than 0.2 and possessing spherical morphology. In comparison to 
dialysis and centrifugation, TFF-based purification was found promising option. The final 
formulation of surface-crosslinked GNPs was found to be free from the residual amounts of 
crosslinker, its by products and excess amounts of poloxamer 188.  
Therefore, it can be concluded that tangential flow filtration is more easy, straightforward and 
efficient approach for the purification of DIC-induced surface crosslinked GNPs. 
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5.1. Abstract  
This chapter is focused on further investigating and proving our working hypothesis of 
colloidal interfacial crosslinking of gelatin nanoparticles in terms of loading a model 
hydrophilic peptide-based drug substance. Furthermore, a hydrophilic non-peptidal 
compound, i.e., fluorescein isothiocyanate labelled dextran with different molecular weights 
was also loaded into these surface-crosslinked GNPs for the assessment of entrapment and 
loading potential and in vitro release kinetics of these surface-crosslinked GNPs and 
comparing the observations with glutaraldehyde crosslinked GNPs. The entrapment potential 
and release kinetics of fluorescein isothiocyanate-dextran was dependent on the molecular 
weight of FITC-dextran. The release of small molecular weight FITC-dextran was faster as 
compared to high molecular weight FITC-dextran.  
The surface crosslinking behaviour by DIC was evaluated in terms of loading therapeutic 
protein-based cargo, i.e., lysozyme. For comparison with a water soluble crosslinker, 
lysozyme loaded glutaraldehyde crosslinked GNPs were also produced with homogenously 
crosslinked GNPs matrix. The lysozyme-loaded gelatin nanoparticles possess mean sizes 
between 200 - 300 nm and a size distribution of PDI < 0.2. The DIC-surface crosslinked 
GNPs demonstrated nearly complete release of lysozyme. The lysozyme released in the 
release medium maintains its enzymatic activity with a negligible loss of activity. In contrast, 
the GTA-crosslinked GNPs showed a hindered in vitro release. These observations revealed 
that the hydrophobic zero length crosslinker (DIC) demonstrates negligible interference in the 
release of lysozyme from gelatin nanoparticulate matrix. In contrast, the hydrophilic 
crosslinker glutaraldehyde shows a strong influence on release of lysozyme and hence a 
significant amount of lysozyme is believed to be permanently entrapped in the gelatin matrix.   
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5.2. Introduction  
In the past few decades, gelatin nanoparticles have been found as interesting nanocarriers for 
different hydrophilic compounds, e.g., nucleic acids, proteins and peptides [169, 170].  
Numerous researchers have observed many fascinating advantages in gelatin nanoparticles 
(GNPs) such as modifiable distribution in the body, tunable drug release and nano-sized 
dimension of particles [171, 172]. The majority of the preparation methods reported for the 
formulation of GNPs are dependent on the chemical crosslinking as a stabilization strategy. 
The main disadvantage of these crosslinkers is that they also crosslink the entrapped protein-
based cargo with the gelatin matrix due to their hydrophilic properties. Consequently, the 
release and biological activity of the encapsulated protein-based hydrophilic macromolecule 
is interfered with. 
Keeping in view this challenge, a stable and optimized formulation consisting of surface 
linked GNPs was established which has been discussed in chapter 3 of this thesis. This was 
possible due to the application of a hydrophobic crosslinker, i.e., diisopropylcarbodiimide. 
The theory of surface-crosslinking was partially supported by TNBS assay, gas 
chromatography and 
1
H-NMR spectroscopic measurements revealing a saturated crosslinking 
process. This saturated crosslinking degree independent of crosslinker concentration and 
crosslinking times was regarded as the first evidence of surface crosslinking. To 
experimentally prove that the hydrophobic zero length crosslinker (DIC) does not crosslink 
the entrapped protein-based payload and preferentially crosslink the GNPs colloidal interface, 
it was necessary to load these surface-crosslinked GNPs with a protein-based macromolecule 
following pre-nanoparticles formation loading procedure and subsequently crosslinking the 
protein loaded GNPs with diisopropylcarbodiimide.  
Therefore, the basic objective of the current chapter is to prove the second part of our working 
hypothesis which can be stated as that hydrophobic crosslinker would not crosslink the 
Characterization and loading of Surface-Crosslinked Gelatin Nanoparticles with Hydrophilic 
Macromolecules 
97 
hydrophilic protein-based payload entrapped in the GNPs matrix; rather it would only 
crosslink the colloidal interface of dispersed GNPs which is necessary for the stabilization of 
GNPs in hydrophilic environments.  
For this purpose, lysozyme was selected as a model peptide-based macromolecule. The 
polypeptide chain of lysozyme contains a total of 129 amino acids a having molecular weight 
of 14.4 kDa with an isoelectric point (IEP) between 10 and 11 [173-175]. Lysozyme was 
loaded to the gelatin polymer matrix prior to nanoparticle formation. T h e  loaded 
GNPs were prepared employing nanoprecipitation followed by crosslinking with crosslinker 
(DIC) using an already optimized concentration (i.e., CDIC = 15 mg/mL). After re-optimization 
of crosslinking conditions for lysozyme-loaded GNPs, the loaded GNPs crosslinked with DIC 
were characterized in terms of particle size, size distribution and zeta potential measurements, 
quantification of entrapment and loading potential, in vitro enzyme release evaluation and 
determination of biological activity. The in vitro release profile and biological assay of the 
encapsulated lysozyme were the major supporting experiments to prove the hypothesis of 
surface crosslinking. Furthermore, a non-peptidal hydrophilic macromolecule, i.e., FITC-
dextran with different molecular weights was also loaded to these surface-crosslinked GNPs 
in order to investigate the loading potential and in vitro release behaviour of these surface 
crosslinked GNPs for non-peptidal substances. The physicochemical properties loaded GNPs 
crosslinked with DIC were compared with glutaraldehyde crosslinked GNPs. 
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5.3. Experimental  
5.3.1. Materials 
Gelatin type B Bloom 75 from bovine skin, poloxamer 188 and diisopropylcarbodiimide 
(reagent grade) were purchased from Sigma-Aldrich (Steinheim, Germany). Acetone (HPLC 
grade) was obtained from Fischer Chemicals Ltd. (Loughborough, U.K.). Milli-Q water with 
a resistivity of 18.2 MΩ.cm was used throughout the experiments. Hen egg white lysozyme 
was purchased from Sigma-Aldrich, Steinheim, Germany. The lyophilized powder of 
Micrococcus lysodeikitus ATCC 4698 cells used a substrate for lysozyme and glutaraldehyde 
aqueous solution (25% w/w, grade II) were purchased from Sigma-Aldrich, Steinheim, 
Germany. FITC-dextran was purchased from TdB Consultancy AB, Uppsala, Sweden. All 
reagents and chemicals used in this research work were of analytical grade and were used as 
received. 
5.3.2. Preparation of loaded gelatin nanoparticles 
Gelatin nanoparticles were prepared using the nanoprecipitation technique (see chapter 3, 
section 3.4.1). Two model hydrophilic macromolecules, i.e., FITC-dextran and lysozyme were 
added to the solvent phase consisting of gelatin solution in water (gelatin concentration in 
water: 20 mg/mL). 
5.3.2.1. Loading with FITC-dextran  
Briefly, 20 mg of gelatin B was dissolved in water and heated up to 50°C. Afterwards, FITC-
dextran (1 mg) with different molecular weights, i.e., 20 kDa, 70 kDa, 150 kDa and 2000 kDa 
was added to gelatin solution. Subsequently, the solvent phase containing gelatin and FITC-
dextran with different molecular weights was added dropwise to the non-solvent phase 
consisting of acetone containing poloxamer 188 (3 % w/v). Afterwards, the FITC-dextran 
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loaded GNPs were crosslinked with 0.347 mL of diisopropylcarbodiimide solution in acetone 
from its stock solution (69.16 % [w/v] for 24 h (see chapter 3 for optimized DIC 
concentration and crosslinking time)). 
5.3.2.2. Loading with lysozyme  
The lysozyme loaded gelatin nanoparticles (GNPs) were prepared following the same 
protocols as mentioned for FITC-dextran loading (section 5.3.2.1). The molecular structure of 
lysozyme contains both primary amino as well as non-bonded carboxylic groups [176] so 
there is maximum probability for chemical crosslinking caused by any crosslinker including 
diisopropylcarbodiimide (see Figure 5-1). 
 
Figure 5-1. Chemical structure of lysozyme. (a) Primary structure. (b) Secondary structure. 
(Reprinted from Phillips et al. (1966) [177]. 
 
Briefly, 20 mg of gelatin was dissolved in 1 mL Milli-Q water at 50°C. Subsequently, 
lysozyme in different drug/polymer ratio was added to the gelatin solution. The drug to 
polymer mass ratios ranged from 2.5 to 40 %. Afterwards, the solvent phase containing both 
gelatin and lysozyme were added dropwise to the non-solvent phase (15 mL acetone 
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containing poloxamer 188 (3% w/v). Following this co-nanoprecipitation, lysozyme loaded 
GNPs are produced which were subsequently crosslinked with an already optimized amount 
of DIC in acetone, i.e., 0.347 mL of diisopropylcarbodiimide solution in acetone from its 
stock solution (69.16 % [w/v]) was added dropwise to the nanosuspension and stirred for 
varying crosslinking times with intermittent DLS measurements in water thus monitoring the 
optimum crosslinking time of lysozyme-loaded GNPs with DIC. In parallel, the same samples 
were also analysed for DLS in acetone as a dispersion medium to investigate the possible 
impact of loading on mean size and size distribution of lysozyme loaded particles. The crude 
nanosuspension of DIC-crosslinked lysozyme loaded GNPs was purified using our pre-
established SOP of tangential flow filtration (TFF) as discussed in previous chapter (see 
section 4.3.3.3). Briefly, the TFF assembly fitted with modified regenerated cellulose 
(Hydrosart) with a pore size of 100 kDa was employed for washing of loaded nanoparticles. 
The preparation procedure is shown schematically in Figure 5-2. 
 




Figure 5-2. Schematic representation of the procedure lysozyme and FITC-dextran loaded 
GNPs via nanoprecipitation and crosslinking the particles by DIC. 
Optimization of lysozyme loading and crosslinking 
In order to investigate the effect of lysozyme loading on optimum crosslinking time which 
was validated for un-loaded GNPs discussed in chapter 3, section 3.4.1, the GNPs suspension 
loaded with varying amounts of lysozyme were incubated for different crosslinking times 
with a fixed concentration of DIC (i.e., 15 mg/mL (already optimized in chapter 3, section 
3.4.1)). The aim was to get lysozyme-loaded GNPs which maintain the particulate integrity in 
aqueous environments with a homogeneous size distribution (PDI < 0.2). The crosslinking 
incubation time was studied for three time points, i.e., 24, 72 and 96 h. In parallel, the DIC 
crosslinked GNPs loaded with different lysozyme amounts were prepared and evaluated using 
DLS measurements to determine the maximum loadable mass of lysozyme. 
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5.3.3. Physicochemical Characterization 
5.3.3.1. Determination of size and size distribution 
After crosslinking for varying crosslinking times, samples of DIC-crosslinked gelatin 
nanoparticles were measured both in acetone and water before purification. The mean size (z-
average mean) and size distribution (PDI) were measured in triplicates for each batch by 
dynamic light scattering (DLS), using the Zetasizer nano-ZS (Malvern instruments, Ltd., 
Malvern, UK). The nano-suspension samples were 10 times diluted with respective dispersion 
media e.g., Milli-Q water and acetone before measurements. 
5.3.3.2. Determination of zeta potential 
Zeta potential of DIC-crosslinked gelatin nanoparticles loaded with varying amounts of 
lysozyme after washing with tangential flow filtration was measured by Laser Doppler 
Anemometry (LDA) at pH 6 using Zetasizer nano-ZS (Malvern Instruments Ltd., 
Worcestershire, UK). All nanoparticles suspensions were 10 times diluted with Milli-Q water 
at 25°C before measurements. Each sample was measured in triplicate. 
5.3.4. Entrapment and loading efficiency 
5.3.4.1. FITC-dextran 
For the determination of entrapment efficiency (% EE), 5 mg of lyophilized nanoparticles 
were dispersed in 5 mL phosphate buffer saline (PBS) at pH 7.4 at room temperature (23 ± 
2°C). To this mixture, trypsin (0.5 mg/mg of polymer) was added to digest the gelatin 
nanoparticles (digestion for 6 h). Subsequently, the digested particles were filtered using 0.2 
µm filter. The samples were analysed using Tecan infinite
®
M200 plate reader (Tecan group 
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Ltd., Männedorf, Switzerland) for the measurement of fluorescence intensity. The 
fluorescence emission intensity was recorded at 520 nm using 485 nm as excitation 
wavelength. For FITC-dextran of each molecular weight, a calibration curve was constructed 
after plotting the fluorescence intensities versus different FITC-dextran concentrations 
(µg/mL). The entrapment efficiency (% EE) was determined using the following equation (5). 
 
% Entrapment Efficiency  = 
Mass of FITC−dextran determinded in the formulation (mg)
Mass FITC−dextran used for the formulation (mg)
 × 100 …(5) 
5.3.4.2. Lysozyme 
In order to avoid the trypsin induced digestion of entrapped lysozyme, un-crosslinked GNPs 
loaded with lysozyme were considered for the determination of entrapment as well as loading 
efficiency. The entrapment and loading efficiencies calculated for un-crosslinked GNPs will 
be regarded as representative for DIC-and GTA crosslinked GNPs. Before quantification of 
lysozyme entrapped in the nanoparticulate matrix, a procedure for isolating the free lysozyme 
from loaded GNPs was optimized. For this purpose, aqueous solution of lysozyme (1 mg/mL) 
was precipitated in acetone (non-solvent) and measured the sizes of precipitated free 
lysozyme without gelatin. Afterwards, the micro-dispersion system of free lysozyme was 
filtered through syringeable micro-filter units consisting of polytetrafluoroethylene (PTFE) 
membrane of 0.45 µm (Millex
®
-FH, Millipore Corporation, City, France). The filtrate was 
analysed for the presence of filtered lysozyme using a validated method of RP-HPLC 
(discussed in the next paragraph). The mass of lysozyme found in the filtrate was subtracted 
from the total amount to calculate the amount of lysozyme retained on the surface of PTFE 
membrane. Likewise, the crude nanosuspension consisting of lysozyme loaded GNPs was 
filtered using the same syringeable PTFE filters 0.45 µm. For the determination of entrapment 
and loading efficiencies, the filtered nano-suspension containing un-crosslinked GNPs loaded 
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with lysozyme were washed with acetone after three times centrifugation (20,000 g for 20 
min) and re-dispersing in acetone. After the third centrifugation, the purified pellet of 
lysozyme-loaded GNPs was isolated followed by air-drying at room temperature. 
Subsequently, 5 mg of un-crosslinked lysozyme loaded nanoparticles pellet was dissolved in 5 
mL phosphate buffer saline (PBS) at pH 7.4 at room temperature (23 ± 2°C). After re-
dissolution of the un-crosslinked gelatin nanoparticles pellet in PBS (pH 7.4), the samples 
were measured using reverse-phase (RP-HPLC) [178] after some necessary modifications in 
the previous method. A calibration curve was constructed after plotting the mean peak areas of 
the standard samples of lysozyme in PBS in the RP-HPLC chromatogram versus the 
corresponding lysozyme concentration (µg/mL). 
In this context, the already reported method of RP-HPLC [178] was re-validated due to a few 
changes in the chromatographic conditions, e.g., packing material of column, column 
dimensions, mobile phase composition and flow rate. For this purpose, an HPLC system 
(Ultimate 3000 series, Rapid Speed, Thermo Fisher Scientific, Waltham, MA, USA), 
equipped with a quaternary pump and a Dionex Ultimate 3000 UV/Vis detector was used. 
Furthermore, the system used an autosampler (ASI-100, Dionex, Sunnyvale, CA, USA), a 
column oven (STH 585, Dionex, Sunnyvale, CA, USA) and a LiChrosphere 100 RP-18e 
column (5 µm material, 4x125 mm, Merck KGaA, Darmstadt, Germany). The column oven 
was heated up to 25 °C. The mobile phase was prepared with degassed and filtered 
acetonitrile and deionized water. The mobile phase used consisted of two solvent systems, i.e., 
mobile phase A and B. Mobile phase-A consisted of 90 % water and 10 % acetonitrile 
acidified with 0.1 % [v/v] trifluoroacetic acid. Mobile phase B consisted of 90 % acetonitrile 
and 10 % Milli-Q water acidified with 0.1 % trifluoroacetic acid [v/v]. The gradient started 
with 100 % mobile phase A acetonitrile and decreased linearly up to 100 % mobile phase B in 
15 min. Afterwards, from 15 to 20 min, the column was equilibrated with 100 % mobile phase 
A. The flow rate of mobile phase was adjusted to 0.8 mL/min. For the detection and 
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quantification of lysozyme, the detector was fixed at 220 nm. The sample injection volume 
selected was 20 µL. The retention time was 8.9 min. For data analysis, the chromatography 
software Chromeleon 6.8 Chromatography Data System (Thermo Fisher Scientific, Waltham, 
MA, USA) was used, and the quantification was based on peak integration with the help of 
software thus recording the area under the chromatographic peak appearing at a retention time 
of 8.9 min. 
The encapsulation efficiency (% E.E) and the loading efficiency (% LE) of lysozyme-loaded 
crosslinked GNPs were calculated using the following equation (6) and (7). 
 
% Entrapment efficiency =  
Mass of lysozyme quantified in NPs [mg]
Total mass of lysozyme added to NPs formulation [mg]
 × 100 ……(6) 
and; 
% Loading efficiency =  
 Mass of lysozyme quantified in NPs [mg]
Mass of GNPs formulation mg]
 × 100……………(7) 
5.3.5. Investigation of in vitro release  
5.3.5.1. FITC-dextran 
For the determination of in vitro release profiles, 10 mg of lyophilized FITC-dextran-loaded 
GNPs were dispersed in 5 mL of PBS (pH 7.4) maintained at 37°C ± 0.5. The release medium 
was stirred at 400 rpm using a mechanical shaker. At pre-determined time points, 1 mL 
supernatant was withdrawn and centrifuged at 20,000 g for 20 min. The pellets were re-
dispersed in 1 mL fresh PBS and added to the original dissolution medium to keep the 
particles concentration constant. The supernatant (1 mL) was analysed for the quantification 
of released FITC-dextran using Infinite
®
 M200 plate reader (Tecan group, Switzerland). For 
recording the fluorescence emission intensities, these excitation and emission wavelengths 
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[λex/λem: 485/520 nm] were used. The % cumulative mass of FITC-dextran released at time 
point (t) was calculated using the following equation (8). 
Cumulative amount of FITC-dextran released at time point (t) [%] =  
Mt
ΣM × 100…………(8) 
Mt: Mass of FITC (mg) released after time point (t). 
Σ M: Total mass of FITC-dextran (mg) entrapped in crosslinked GNPs. 
5.3.5.2. Lysozyme 
For the determination of in vitro release profile of lysozyme, 10 mg of dried powder of 
lysozyme-loaded GNPs was dispersed in 5 mL of PBS (pH 7.4) maintained at 37°C ± 0.5. The 
release medium was stirred at 400 rpm using a mechanical shaker. At pre-determined time 
points, 1 mL supernatant was withdrawn and centrifuged at 20,000 g for 20 min. Then 1 mL 
aliquots were withdrawn from the supernatant and the pellet was re-dispersed in 1 mL PBS 
and added to the original release medium to maintain the particles concentration constant in 
the release medium. The aliquots withdrawn (1mL) were analysed using a validated procedure 
of RP-HPLC mentioned in section 5.3.4.2 for the quantification of lysozyme concentration 
released at that particular time point. Afterwards, the % cumulative mass of lysozyme released 
from crosslinked GNPs at its corresponding time points was calculated using the following 
equation (9). 
Cumulative amount of lysozyme released [%] after time point (t) =  
Mt
ΣM × 100……………(9) 
Mt: Mass of lysozyme (mg) released after time point (t). 
Σ M: Total mass of lysozyme (mg) entrapped in crosslinked GNPs. 
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5.3.6. Determination of the biological activity 
This is a turbidimetric bioassay which involves the measurement of turbidity clearance 
potential of lysozyme after incubating it with its substrate. This turbidimetric assay is based 
on the hydrolytic activity of lysozyme on the substrate which consisted of lyophilized powder 
of a gram positive bacterium called Micrococcus lysodeikticus ATCC No. 4698 cells. The 
measurement of enzymatic activity of lysozyme entrapped in DIC-crosslinked GNPs was 
performed using standard protocols of turbidimetric bioassay as provided by the manufacturer 
(Sigma-Aldrich) [179]. The objective was to determine whether the lysozyme after 
entrapment in DIC and GTA-crosslinked gelatin nanoparticles maintains its intended 
biological activity or not. The lysozyme digests the bacterial cell wall by hydrolysing the β 
(1,4)-glycosidic linkages between N-acetylmuramic acid (NAM) and N-acetyl glucose amine 
(NAG) [180, 181]. The following protocols of turbidimetric assay were used. Firstly, the 
substrate suspension in a concentration (0.015 % w/v) was prepared after dispersing a known 
amount of lyophilized powder of Micrococcus lysodeikitus in phosphate buffer saline (PBS) at 
pH 7.4. Afterwards, 2.5 mL from this substrate suspension was transfered to quartz cuvette 
having path length of 1 cm. Subsequently, 100 µL of lysozyme calibration standards or 
release samples of crosslinked GNPs was added to the substrate suspension in the cuvette and 
the mixture was homogeneously mixed by inversion. The decrease in absorption was recorded 
at 450 nm (ΔA450nm) for 5 minutes using a UV/VIS spectrophotometer at 25°C. The turbidity 
clearance potential of lysozyme expressed as absorption change per unit time represented by 
ΔA450nm/min was considered as a quantification parameter for the lysozyme enzymatic 
activity. For the activity-based quantification of lysozyme, a calibration curve was constructed 
after plotting the absorption change per unit time [ΔA450nm/min] against the corresponding 
concentrations of lysozyme (µg/mL). Likewise, the supernatants of DIC- as well as GTA-
crosslinked nanoparticles containing the released lysozyme in the release media were 
analysed in the same way as the calibration standards. Briefly, 8 mg of lyophilized 
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crosslinked gelatin nanoparticles were dispersed in 4 mL PBS buffer at pH 7.4 at 37°C and 
incubated for 24 h with continuous stirring at 400 rpm. After 24 h, the release mixture was 
centrifuged at 15,000 g for 10 min. From the supernatant, a 0.1 mL aliquot was withdrawn 
and the activity was checked in the same way as described above for the calibration standards 
of lysozyme. Afterwards, the biological activity in terms of turbidity clearance potential 
expressed as absorption change per unit min (i.e., ΔA450nm/min) was converted to 
corresponding mass of lysozyme which is biologically active using the turbidimetric bioassay-
based calibration curve. The same samples were also analysed simultaneously using the 
validated RP-HPLC for the determination of total released mass of lysozyme in the release 
medium. Moreover, the biologically active mass of lysozyme measured with turbidimetric 
assay was compared with the amount calculated on the basis of reverse-phase HPLC. From 
this correlation, the biologically active mass of lysozyme was estimated. 
5.4. Results and Discussion 
Both FITC-dextran and lysozyme loaded GNPs were prepared following the standard 
protocols as already mentioned (section 5.3.2, Figure 5-2). Pre-nanoparticle formation loading 
procedure was employed for loading these hydrophilic macromolecules into GNPs. In the 
case of FITC-dextran loading, 1 mg of FITC dextran of different molecular weights (20 kDa, 
70 kDa, 150 kDa and 2000 kDa) was loaded into GNPs, while in case of lysozyme loading, 
different % mass ratios of lysozyme-to-gelatin were used, i.e.,  2.5, 5, 10, 25, 30 and 40 %.  
During nanoprecipitation, both the payloads, i.e., FITC-dextran and lysozyme, are co-
nanoprecipitated with gelatin during diffusion to non-solvent phase resulting in the formation 
of FITC-dextran loaded GNPs and lysozyme-loaded GNPs. Due to hydrophilicity, both the 
FITC-dextran and lysozyme diffuse to gelatin phase during the nanoprecipitation process 
leading to the entrapment of hydrophilic macromolecules in gelatin nanoparticulate matrix. 
Subsequently, the influence of loading of these hydrophilic macromolecules on 
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physicochemical properties of GNPs, e.g., mean particle size (Z-average), size distribution 
characterized by polydispersity index and zeta potential were evaluated.   
5.4.1. Effect of loading on mean size and size distribution 
5.4.1.1. FITC-dextran loaded GNPs 
It was observed that the loading of FITC-dextran in a drug to polymer mass ratio of 1:20 has 
no influence on mean size of loaded gelatin nanoparticles irrespective of molecular weight of 
FITC-dextran (Figure 5-3, Table 5-1). The mean size of loaded and un-loaded GNPs is 
between 230 - 250 nm, but the polydispersity index (PDI) is increasing with loading of FITC 
dextran. The PDI of un-loaded GNPs was less than 0.2 while the loaded GNPs possess PDI 
from 0.2 - 0.3. Besides, the optimum crosslinking time of FITC-dextran loaded GNPs was 
found similar to un-loaded GNPs as can be seen in Table 5-1. For both loaded and un-loaded 
GNPs, the optimum crosslinking time is approximately 20 - 24 h. It means that the loading of 
FITC-dextran has no significant impact on optimum crosslinking times as optimized in 
chapter 3 for un-loaded nanoparticles (Figure 5-3). 




Figure 5-3. Effect of FITC-dextran (1mg) loading of different molecular weights on mean size 
and size distribution of produced gelatin nanoparticles. The FITC-dextran to gelatin mass 
ratio was 1:20. Statistics: (N.S: Not significant statistically as per one-way ANOVA (p > 
0.05) 
 
Table 5-1. Mean sizes and size distribution of FITC-dextran loaded GNPs crosslinked with 
DIC used in a concentration of 15 mg/mL in nanosuspension 
FITC-dextran loaded 
GNPs 
Mean size [nm] ± 
S.D. 
Mean PDI ± S.D. Crosslinking time 
(h) 
Unloaded (blank) GNPs 241.48 ± 19.18 0.10 ± 0.04 20-24 
FITC-dextran 20 kDa 240.88 ± 24.92 
 
0.18 ± 0.04 
 
20-24 
FITC-dextran 70 kDa 251.08 ± 10.41 
 
0.20 ± 0.03 20-24 
FITC-dextran 150 kDa 247.23 ± 29.62 
 
0.19 ± 0.08 20-24 
FITC-dextran 2000 kDa 250.03 ± 23.42 
 
0.19 ± 0.05 20-24 
N.S.
a
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5.4.1.2. Lysozyme loaded GNPs 
The lysozyme loaded gelatin nanoparticles prepared via nanoprecipitation as shown in Figure 
5-2 were crosslinked with 0.347 mL diisopropylcarbodiimide solution (taken from stock 
solution of DIC in acetone having concentration of 69.16 % w/v) at room temperature. The 
concentration of DIC in total bulk of nanosuspension is 15 mg/mL which was optimized in 
chapter 3. It was observed that no apparent change in mean size was observed with lysozyme 
loading below 5 %. Increasing the mass ratio above 5 or 10 % slightly increased the mean size 
of GNPs as can be seen in Figure 5-4. However, the maximum loadable amount of lysozyme 
was found to be 25 % [lysozyme/gelatin]. Increasing the amount above 25 % resulted in the 
formation of bigger visible precipitates, which consequently leads to phase separation of the 
entire bulk dispersion system as can be seen in Figure 5-4. 
  





Figure 5-4. Mean size and size distribution analysis of DIC-crosslinked GNPs loaded with 
different drug to polymer mass ratio at room temperature for DIC concentration of 15 mg/mL. 
The samples were measured in acetone as a dispersant and were diluted 10 times with acetone 
before DLS measurements. Statistics (N.S.: statistically non-significant on the basis of 
p > 0.05 as per one-way ANOVA). (*) p ˂ 0.05: Statistically significant as per one-way 
ANOVA. 
 
Overall, the mean hydrodynamic diameter of lysozyme-loaded GNPs is increased by an 
increment of approximately 15 - 30 nm using lysozyme of 25 %. The increase in mean size of 
DIC-crosslinked GNPs loaded with lysozyme above 5 % may be attributed to an increase in 
viscosity of the solvent phase with higher lysozyme amounts. The higher the viscosity of 
solvent phase, the slower will be the diffusion rate of the solvent phase into the non-solvent 
phase during particles formation in nanoprecipitation [99]. This leads to formation of bigger 
particles.  
During preparation of DIC-crosslinked lysozyme loaded gelatin nanoparticles, another 
observation was the pronounced impact on optimum crosslinking time. After loading 
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lysozyme above 5 %, the loaded particles were not stable in water for crosslinking time of 
24 - 28 h. So, it needs re-optimization of the crosslinking time which is explained in the 
following section (see section 5.4.2). 
5.4.2. Optimization of crosslinking time for lysozyme loading 
The physicochemical integrity of DIC-crosslinked GNPs loaded with lysozyme in varying 
amounts in aqueous medium need to be re-evaluated. The optimization of crosslinking time 
for blank gelatin nanoparticles has been discussed in detail in chapter 3 sub-section 3.4.1. For 
the re-optimization of crosslinking time for lysozyme-loaded GNPs, the time interval after 
which the polydispersity index (PDI) was below 0.2 while measuring the DIC-GNPs in water 
was considered as optimum crosslinking time. In this experiment, the samples from DIC-
crosslinked GNPs dispersion were taken after different time points and measured in water 
using DLS. It was observed that the optimum crosslinking time is also affected with 
increasing the amount of loaded lysozyme in the solvent phase. Using lysozyme amount up to 
2.5 % does not affect the crosslinking time which is optimum for un-loaded GNPs (i.e., 
approximately 16 - 24 h) keeping the crosslinker concentration constant (i.e., 15 mg/mL) at 
room temperature. Increasing the amount of lysozyme in the solvent phase above 5 % leads to 
an increase in the optimum crosslinking time. In this way, the corresponding optimum 
crosslinking times for 2.5, 5, 10 and 25 % lysozyme were 24 h, 24 - 48 h, 72 h, and 96 h, 
respectively as can be seen in Table 5-2 and Figure 5-5. At these incubation times, the PDI 
was less than 0.2.  
After optimizing the crosslinking times for the above lysozyme amounts, the mean size and 
size distribution of crosslinked GNPs loaded with lysozyme were measured both in acetone 
and water using DLS as shown in Figure 5-6 and Table 5-2. The mean sizes measured in 
acetone are smaller than the measured sizes in water. This might be due to swelling 
phenomenon which happens when the crosslinked gelatin nanoparticles are transferred from 
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organic phase (acetone) to aqueous phase (water). In fact, the crosslinked GNPs act as a nano-
hydrogel system. The same phenomenon was also observed for un-loaded DIC-crosslinked 
GNPs (see chapter 3, Figure 3-8, Table 3-9 and Table 3-10). 
 
 
Figure 5-5. Mean size and size distribution analysis of lysozyme-loaded GNPs loaded with 
different amounts of lysozymes at different incubation times at room temperature 
(concentration of DIC was 15 mg/mL). Samples were measured in water as a dispersant for 
DLS measurements and each sample was diluted 10 times in water before measurements. 
 
Table 5-2. Effect of lysozyme loading on mean size, size distribution and optimum 
crosslinking time (h) of DIC-crosslinked GNPs loaded with different amounts of lysozyme. 





Mean size [nm] ± SD (PDI) 
Measured in acetone 
(before washing) 
Measured in water (before 
washing) 
Blank GNPs 24 184.20 ± 5.18 (0.09) 268.40 ± 7.75 (0.12) 
2.5 24 180.15 ± 9.49 (0.08) 262.79 ± 20.98 (0.12) 
5 72 186.83 ± 7.27 (0.08) 255.88 ± 16.65(0.11) 
10 96 205.59 ± 9.76 (0.09) 279.5± 12.13(0.11) 







: Not determined due to visible precipitates formation. CT*: crosslinking time 
 




Figure 5-6. Mean size and size distribution analysis of DIC-crosslinked GNPs loaded with 
different lysozyme amounts. The DIC concentration used was 15 mg/mL. The samples were 
measured both in acetone and water as dispersion media and were diluted 10 times before 
DLS measurements. Each sample was measured in triplicates with three independent 
experiments. Statistics: (*) p ˂ 0.05: Statistically significant according to paired two-tail t-
test. 
 
The increase in optimum crosslinking time can be explained in terms of electrostatic 
interaction between the negatively charged carrier molecule (gelatin B having IEP of 4.7-5.4) 
[54, 139] and positively charged cargo molecule (lysozyme, with IEP between 9 and 11) [19, 
182]. Due to the difference of isoelectric points (IEPs) between gelatin B and lysozyme, the 
electrostatic interaction between the peptidal cargo (lysozyme) and carrier molecule (gelatin) 
would be dominant. This phenomenon is called poly-ionic complexation [183]. The 
electrostatic interaction between the negatively charged gelatin matrix and positively charged 
enzyme has also been investigated by other researchers [184]. From these literatures, it is 
apparent that the majority of negatively charged carboxylic groups are electrostatically 
connected with the positively charged amino groups of lysozyme. Consequently, a very low 
population of free carboxylic groups would be available for crosslinking at the colloidal 
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interface, and hence, the process of crosslinking would be delayed. Since, the rate determining 
step in DIC-mediated crosslinking is the activation of carboxylic groups leading to the 
formation of an unstable transition complex, known as O-Acylisourea (see chapter 3, Figure 
3-3 b). Subsequently, this intermediate is readily attacked by a nucleophile (e.g., primary 
amino groups). Therefore, this delaying of crosslink formation is believed to be accountable 
for an increase in the crosslinking time with loading of lysozyme above 5 %. That is, the 
higher the amount of loaded lysozyme, the higher will be the degree of electrostatic 
interaction between gelatin and lysozyme, the more carboxylic groups would be engaged in 
the electrostatic interaction, and the slower will be the crosslinking rate with DIC. Besides, 
some fraction of lysozyme is also believed to be adsorbed onto the colloidal interface 
especially in higher lysozyme loads (e.g., > 5 %), which will constitute a poly-ionic complex 
at the colloidal interface. In turn, this would interfere with the normal crosslinking chemistry 
caused by the DIC which may lead to an increase in the optimum crosslinking time. 
Therefore, the GNPs loaded with higher amounts of lysozyme need comparatively more time 
for stabilization. 
In contrast, in the case of loading of lower amounts of lysozyme, low fraction of free 
carboxylic groups of gelatin would be engaged in the electrostatic interaction with lysozyme 
molecules, and hence more free carboxylic groups would be available on GNPs surface for 
DIC-mediated crosslinking. So, the electrostatic complexation between lysozyme and gelatin 
on the colloidal interface may affect the DIC crosslinking kinetics. The larger the extent of 
electrostatic interaction between lysozyme and gelatin the higher amounts of lysozyme, 
higher will be the optimum crosslinking times for the optimum stability of GNPs and vice 
versa. 
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5.4.3. Determination of zeta potential 
As discussed previously, gelatin B is an acidic polymer having isoelectric point (IEP) of 4.7-
5.4 [139], while the lysozyme is a basic polypeptide macromolecule having isoelectric point 
of between 10-11[173, 174, 182]. Due to the basic isoelectric point of lysozyme, the lysozyme 
will exist as predominantly cationic polypeptidal molecule. In this experiment, the zeta 
potential of DIC-crosslinked gelatin nanoparticles loaded with different amounts of lysozyme 
was measured at pH 6. It is evident from Figure 5-7 and Table 5-3 that the zeta potential of 
lysozyme-loaded GNPs is similar to the zeta potential of unloaded GNPs with lysozyme 
loading up to 5 %. The positive zeta potential increases proportionately with increasing the 
amount of loaded lysozyme above 5 %. This observation has also been reported in the 
literature [125]. The increase in positive zeta potential may be attributed to the surface 
adsorbed lysozyme while loading lysozyme above 5 %. In contrast, for the lysozyme loading 
below 5 %, there is low possibility of surface adsorbed lysozyme onto surface crosslinked 
GNPs, and possibly, a significant fraction of lysozyme is believed to be entrapped in the core 
of DIC crosslinked GNPs. Due to high isoelectric point of lysozyme (~ 11.4), the net charge 
of lysozyme at pH 6 will be positive due to the predominance of protonated amino groups 
(NH3
+
 groups) present on the molecule. Hence, it was expected that the zeta potential of 
lysozyme-loaded GNPs should be more positive as compared to blank GNPs due to the 
predominance of more protonated cationic groups (e.g., 
+
NH3 groups) contributed by the 
surface anchored/adsorbed lysozyme molecules.  




Figure 5-7. Zeta potential of DIC-crosslinked GNPs loaded with different amounts of 
lysozyme measured at pH 6. Statistics (N.S: non-significant statistically (p > 0.05), (*) p ˂ 
0.05:  Statistically significant as per one-way ANOVA. 
 
Table 5-3. Zeta potential profile of Lysozyme-loaded GNPs crosslinked with DIC at pH 6.  
S.No. Formulation Mass ratio 
[Lysozyme/gelatin] % 
Zeta potential [mV] ± SD 
1 Unloaded GNPs - 9.94 ± 2.30 
2 Lysozyme-loaded GNPs 2.5 10.56 ± 2.35 
3 Lysozyme-loaded GNPs 5 10.67 ± 0.76 
4 Lysozyme-loaded GNPs 10 28.14± 0.97 
5.4.4. Entrapment and loading efficiency 
5.4.4.1. FITC-dextran 
The entrapment efficiency of DIC-crosslinked GNPs increases with increase in molecular 
weight of FITC-dextran. For FITC dextran (20 kDa, 70 kDa, 150 kDa and 2000 kDa), the 
entrapment efficiency observed was approximately 3 %., 13.57 %, 36.14 % and 82.62 %, 
respectively, as can be seen in Figure 5-8. The possible reason for low entrapment efficiency 
of low molecular weight FITC-dextran is the pre-release of FITC-dextran molecules during 
purification step of nanoparticles. In contrast, FITC-dextran of high molecular weight is 
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believed to be strongly embedded in the nanoparticulate matrix of gelatin, hence is not easily 
released during washing step. Consequently, this results in an apparent higher entrapment 
efficiency. This type of relationship between entrapment efficiency and molecular weight of 
FITC-dextran has also been reported by other researchers [123, 185].  
It is also evident from this data that glutaraldehyde crosslinked GNPs loaded with FITC-
dextran possess comparatively higher entrapment efficiency as compared to DIC-crosslinked 
GNPs as can be seen in Figure 5-8. This is probably due to a difference of swelling potential 
of two types of nano-hydrogel systems due to differences of crosslinking degrees between the 
two types of crosslinkers. The glutaraldehyde induced crosslinking of GNPs demonstrates a 
crosslinking degree of approximately 72 % as has been investigated previously in our group 
[123]. On the other hand, the DIC-crosslinked GNPs demonstrated approximately 25 % 
crosslinking degree (see chapter 3, section 3.4.2.1). Furthermore, the two types of crosslinkers 
establish different crosslinks within the gelatin peptide networks. Glutaraldehyde establish a 
Schiff’s base within the gelatin peptide network [104] while DIC is believed to induce amide 
bonds within the gelatin peptide network just like other carbodiimides [131-134]. 
Therefore, the glutaraldehyde-crosslinked GNPs are homogenously crosslinked nanocarriers 
which are comparatively rigid nanostructures due to higher crosslinking degree as compared 
to DIC-crosslinked GNPs which have been hypothesized to be crosslinked only on the 
colloidal interface with a lower degree of crosslinking. 
In summary, due to the difference of crosslinking degrees between the two types of 
crosslinked GNPs, the extent of pre-release or diffusion of FITC-dextran to the external 
aqueous environment during washing of nanoparticles is different. According to literature, the 
same phenomenon, i.e., dependency of release or diffusion of encapsulated cargo in GNPs on 
crosslinking degree, has also been observed by other investigators [66, 71, 186] 
 
 




Figure 5-8. Comparison of entrapment efficiency between GTA-crosslinked and DIC-
crosslinked GNPs and effect of molecular weight of FITC-dextran on entrapment potential of 
both types of GNP systems. Statistics (n.s.: statistically non-significant on the basis of p > 
0.05 using t-test.  (*) Statistically significant p ˂ 0.05  
 
Due to the differences in crosslinking degree and crosslink networks inside gelatin matrix, the 
entrapped FITC-dextran in glutaraldehyde crosslinked GNPs are not easily washed with water 
during purification step in contrary to DIC-crosslinked GNPs which show comparatively 
higher rate of leakage of entrapped FITC-dextran during particles purification step. Secondly, 
the FITC-dextran of lower molecular weight exhibits higher leakage as compared to high 
molecular weight FITC-dextran for both types of crosslinkers. Similar behaviour has also 
been previously reported for glutaraldehyde crosslinked gelatin nanoparticles encapsulated 
with FITC-dextran of different molecular weights [123]. 
5.4.4.2. Lysozyme 
Before the measurement of the total mass of entrapped lysozyme in GNPs matrix, the 
procedure for isolating the free (or un-entrapped) lysozyme from loaded GNPs was validated. 
For this purpose, aqueous solution of lysozyme (1 mg/mL) without addition of gelatin was 
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precipitated in acetone (15 mL) both with and without stabilizers (poloxamer 3% w/v). The 
DLS measurements demonstrated that the precipitated free lysozyme exists as visible 
marcroscopic aggregates following precipitation in acetone as can be seen in Figure 5-9. 
These marcroscopic aggregates can be separated using syringe filters composed of acetone 
resistant material, i.e., polytetrafluoroetehylene (PTFE) with a pore size of 0.45 µm. After 
microfiltration of the denatured free lysozyme, the filtrate was analysed for the amount of free 
lysozyme in filtrate fraction using reversed phase HPLC. From this amount, the fraction of 
lysozyme retained on top of the membrane was calculated after subtracting the filtered mass 
from total mass. It was observed that 100 percent of lysozyme is retained on top of the 
membrane because of the sizes of the macroscopic aggregates are larger than the pore size of 
the membrane (see Figure 5-10 (b)). Therefore, it can be concluded from this experiment that 
all free or un-entrapped fraction of lysozyme will be retained on top of the PTFE membrane 
having pore size of 0.45 µm during filtration. Likewise, after filtration of lysozyme-loaded 
GNPs suspension (un-crosslinked) using 0.45 µm PTFE filters, the quantity of entrapped 
lysozyme was analysed after centrifugation and subsequently dissolving the particles in PBS 
at pH 7.4. In another experiment, the un-filtered GNPs (un-crosslinked) loaded with similar 
amount of lysozyme were centrifuged and analysed after dissolving the pellet in PBS at pH 
7.4. It was found that the entrapment efficiency of filtered GNPs was almost similar to non-
filtered GNPs (see Figure 5-10 a and Table 5-4). 
In summary, these validation experiments demonstrates that un-entrapped lysozyme exists in 
the form of micro-sized precipitates which can be isolated by micro-filtration from lysozyme-
loaded GNPs. The lysozyme loaded GNPs will pass through the microfilters while free 
lysozyme micro-sized precipitates will be retained on the membrane surface. In accordance 
with the results of this validation experiment, the amount of lysozyme present in loaded GNPs 
after microfiltration was found almost equivalent to lysozyme amounts calculated for the non-
filtered GNPs. This means that almost all the enzyme is entrapped in GNPs which is being 
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filtered across the PTFE filter of 0.45 µm. The entrapment and loading efficiency of un-
crosslinked GNPs loaded with different amounts of lysozyme are summarized in  
Figure 5-11 (a) and Figure 5-11 (b),  respectively. The loaded GNPs without micro-
filtration were analysed for entrapment and loading efficiencies. It can be observed that the 
entrapment efficiency is above 80 % for all amounts of lysozyme. The loading is constantly 
increasing and can be adjusted to 12 % (see Figure 5-11 (a) and (b).  
 
 
Figure 5-9. Mean sizes of free lysozyme having concentration of 2 mg/mL in water dispersed 
in acetone. The mean sizes are in the micro-range.  
  





Figure 5-10. Microfiltration of free lysozyme dispersed in acetone and lysozyme-loaded 
GNPs. (a). Entrapment efficiency of lysozyme-loaded un-crosslinked GNPs with and without 
microfiltration of nanosuspension using PTFE syringe filters (0.45 µm pore size). (b) % 
lysozyme retained on membrane surface after microfiltration of free lysozyme dispersion in 
acetone using µm 0.45 PTFE filter. Statistics (N.S: statistically non-significant on the basis of 
of p > 0.05 using t-test. 
 
Table 5-4. Comparison of entrapment efficiencies of lysozyme-loaded GNPs with and without 
microfiltration using PTFE syringe filters (0.45µm pore size). 
S.No Formulation  Entrapment efficiency 
[%] 
1 Lysozyme loaded GNPs (without filtration) 96.53 ± 2.00 
2 Lysozyme loaded GNPs (after filtration with 0.45 µm 
PTFE membrane) 
93.97 ± 3.78 
 




Figure 5-11. (a) Entrapment efficiency of DIC-crosslinked GNPs loaded with different 
amounts of lysozyme (% EE was calculated for lysozyme-loaded GNPs without 
microfiltration. (b) Loading efficiency of GNPs loaded with different amounts of lysozyme. 
Loaded GNPs without microfiltration were analysed. Statistics (N.S.: statistically non-
significant on the basis of p > 0.01 as per one-way ANOVA and t-test; (*) p < 0.05) 
5.4.5. Summary of the physicochemical properties of lysozyme-loaded GNPs 
In summary, the mean size of lysozyme-loaded nanoparticles does not change significantly 
with using lysozyme/gelatin up to 5-10 % (see Table 5-5). However, there is slight increase in 
mean size of about (15-30 nm) with loading of lysozyme above 10 % up to 25 %. For all 
formulations, the PDI was found to be below 0.2 showing a narrow size distribution. With 
loading of lysozyme above 25 % led to visible precipitates formation which ultimately led to 
phase separation of the dispersion system. Thus, the maximum loadable lysozyme-to-gelatin 
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ratio was found to be 25 %. The zeta potential values of lysozyme-GNPs loaded with different 
lysozyme amounts measured at pH 6 were compared with the unloaded GNPs (see Table 5-5). 
It was observed that the zeta potential of blank GNPs and lysozyme-loaded GNPs loaded with 
lysozyme up to 5 % is similar. On the other hand, the positive zeta potential increases with 
increasing the amount of loaded lysozyme above 5%. The highly positive zeta potential of 
lysozyme–loaded GNPs could be attributed to the surface adsorbed lysozyme molecules 
which exist as cationic molecules because of its high isoelectric point (IEP 11-12). The 
entrapment efficiency is above 80 % for all amounts of loaded lysozyme. The loading is 
constantly increasing and the maximum loading efficiency achievable is 12 %. 
Table 5-5. Summary of the physicochemical properties of lysozyme-loaded GNPs crosslinked 





Size ± S.D. 
[nm] 
PDI ± S.D. Zeta potential 









184.19 ± 5.20 0.09 ± 0.05 9.94 ± 2.30 - - 
2.5 178.84 ± 10.26 0.07 ± 0.01 10.56 ± 2.35 99.60 ± 3.35 3.35 ± 1.33 
5 184.76 ± 7.20 0.08 ± 0.02 10.67 ± 0.76 87.01 ± 4.79 4.79 ± 1.16 
10 205.00 ± 10.00 0.09 ± 0.02 28.14 ± 0.97 93.97 ± 9.87 9.87 ± 1.71 












40 - - - -
 
- 
50 - - - - - 
ND
a
: Not determined due to visible precipitate formation. 
(b)
 All samples were measured in 
acetone as dispersion medium for the DLS measurements and were 10 times diluted with 
acetone before measurements. The data is an average of three independent experiments.  
5.4.6. Investigation of in vitro release 
5.4.6.1. FITC-dextran 
The in vitro release profile of DIC-crosslinked GNPs loaded with different molecular weight 
FITC-dextran has been shown in Figure 5-12. The rate and extent of FITC-dextran release is 
different for different molecular weights. It can be observed that FITC-dextran of low 
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molecular weight shows faster release as compared to high molecular weight FITC-dextran 
(see Figure 5-12). For example, the FITC-dextran 20 kDa and 70 kDa showed almost 20 % 
release in the first 30 minutes. After 8 h, the FITC-dextran 20 kDa was released completely, 
while the FITC-dextran 70 kDa achieved a plateau concentration of around 40 % after 24 h. In 
the case of FITC-dextran 150 kDa, almost 40 % FITC-dextran was released after 72 h 
followed by a continuous release for 120 h. In the case of FITC dextran 2000 kDa, almost 17 
% release was observed after 24 h which was maintained at 17 % for 120 h (see Figure 5-12).  
It has been previously reported that the slow release of high molecular weight FITC-dextran is 
not associated with the crosslinking of payload with the gelatin polymer as dextran is a 
polysaccharide lacking primary amino groups [98]. According to literature, it is believed that 
on contact with aqueous buffer, some pores or channels of defined porosity are produced in 
the gelatin matrix which are bigger than the low molecular weight FITC-dextran but smaller 
than the high molecular weight FITC-dextran. In the case of high molecular weight FITC 
dextran, after the releases of surface adsorbed FITC-dextran, the rest of payload is retained in 
the matrix of gelatin nanoparticles. In terms release kinetics pattern, almost similar release 
behaviour, i.e., dependency of release kinetics on molecular weight of FITC-dextran has also 
been reported for glutaraldehyde crosslinked GNPs [98].  
 




Figure 5-12. In vitro release profile of DIC-crosslinked gelatin nanoparticles loaded with 
FITC-dextran of different molecular weight in phosphate buffer saline (PBS) pH 7.4 as 
release medium at 37 °C. 
5.4.6.2. Lysozyme 
The in vitro release profile of lysozyme from DIC-crosslinked GNPs demonstrated that about 
40% of lysozyme was released in the initial 0.5 h (Figure 5-13). This fast burst release has 
also been reported by other investigators [125]. The burst release of approximately 40-50 % 
was followed by a sustained release up to an extent of 90-100 % for 24 h. Lysozyme is a 
cationic polypeptide composed of 129 amino acids containing many basic as well as acidic 
amino acid residues [187] thus providing a favourable environment for crosslinking reaction 
by crosslinker (e.g., DIC). Nevertheless, the maximum release of approximately 90-100 % 
release of lysozyme from DIC-crosslinked GNPs matrix reveals that the hydrophobic 
crosslinker, diisopropylcarbodiimide, is slightly involved in the crosslinking of lysozyme with 
gelatin thus allowing high fraction of lysozyme released in the medium. In contrast, the 
release from the GNPs stabilized by glutaraldehyde crosslinking demonstrated that some 
fraction of lysozyme (approximately 30-40 %) is released while a significant fraction 
(approximately 60-70 %) is still not released. Since, glutaraldehyde is a hydrophilic homo-
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bifunctional crosslinker which homogenously diffuses into the core of nanoparticulate matrix, 
it is believed that this low extent of release of lysozyme from glutaraldehyde crosslinked 
gelatin matrix is due to inter-molecular (lysozyme-gelatin) crosslinking following the 
formation of covalent linkages, i.e., Schiff’s bases. Therefore, it can be concluded that the 
crosslinker, diisopropylcarbodiimide, due to its hydrophobicity has a limited diffusion to the 
hydrophilic core of gelatin nanoparticles. Presumably, the surface restricted crosslinking 
behaviour of DIC due to its hydrophobic nature, led to the formation of surface crosslinked 
gelatin nanoparticles entrapping a hydrophilic peptidal cargo without being crosslinked inter-
molecularly with GNPs matrix. 
 
Figure 5-13. In vitro release profile of DIC-crosslinked and glutaraldehyde crosslinked GNPs 
loaded with different amounts of lysozyme in phosphate buffer saline (PBS) pH 7.4 as a 
release medium at 37°C. Statistics (N.S.: statistically non-significant on the basis of p > 0.05 
as per one-way ANOVA). 
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5.4.7. Determination of biological activity  
There is a linear relationship between lysozyme concentration and its corresponding 
enzymatic activity which was expressed in terms of turbidity clearance potential of its 
substrate suspension, i.e., Micrococcus lysodeikticus ATCC No. 4698 cells. The turbidity 
lowering potential can be characterized as absorption change per unit time (i.e., ΔA/min). It 
was observed that the correlation between enzyme concentration and its activity was linear up 
to a concertation of approximately 80 µg/mL as shown in Figure 5-14. Further increase in 
enzyme concentration has almost no influence on enzymatic activity. This phenomenon was 
expected as this is a general behaviour of all enzymes [188]. The enzymatic activity increases 
with increase in enzyme concentration at a given substrate concentration until an equilibrium 
is achieved. Further increase in enzyme concentration has no impact on enzymatic activity 
because of the substrate saturation with enzyme.  
Moreover, when the rate of enzymatic reaction of lysozyme was studied after every minute 
for five minutes interval, it was observed that the rate of enzymatic reaction of lysozyme was 
found to be non-uniform. The activity is high initially (i.e., during first minute) which slowly 
declines after each minute. This can be observed in the enzyme kinetics curves in Figure 5-15. 
Therefore, the enzymatic reaction rate during first minute which is the highest activity 
response was considered for making calibration curve as shown in Figure 5-14 (b).  




Figure 5-14.(a): Relationship between enzyme concentration (µg/mL) and corresponding 
enzymatic activity (ΔA/min). (b): Calibration curve of lysozyme based on turbidimetric assay 
(Linearity between enzyme concentration and corresponding enzymatic activity in the 
concentration range of 5-80 µg/mL) 
  




Figure 5-15. Standard kinetic curves using turbidimetric assay. The enzymatic activity is high 





For the turbidimetry-based bioassay, the release samples from DIC and glutaraldehyde 
crosslinked GNPs were analysed after incubation of 8 mg of dried powder of lysozyme-
loaded GNPs in 4 mL of PBS (pH 7.4) for 24 h at 37°C accompanied by continuous 
mechanical shaking at 400 rpm. The same samples were also analysed using the validated 
method of reverse-phase HPLC. Consequently, the calibration curve shown in Figure 5-16 
was used for the determination of the total mass of released lysozyme from crosslinked (both 
DIC and GTA crosslinked gelatin nanoparticles. 
The comparison between released lysozymes from GTA-crosslinked GNPs and DIC-
crosslinked GNPs is summarized in Table 5-6. 
 
 




Figure 5-16. Calibration curve of lysozyme based on RP-HPLC 
 
Table 5-6. Comparison between lysozyme amounts analysed via bioassay and HPLC assay 
Sampling time 
[h] 






Bioassay  HPLC  Bioassay  HPLC  
24 
36.67 ± 4.26 48.11 ± 2.83 84.42 ± 8.18 95.15 ± 7.50 
The data is an average of three independent experiments (n=3).
 (a)
Crosslinking time: 24 h. 
Due to short crosslinking time, the release of lysozyme is comparatively higher than the 
release of previous experiment (5.4.6.2) in which the crosslinking time was 48 h. 
(b)
Crosslinking time: 48 h 
 
It is evident from the HPLC- and turbidimetry-based quantification of the released amount of 
lysozyme that the release extent from the DIC-crosslinked system is more as compared to the 
GTA-crosslinked system. The same phenomenon was also observed in section 5.4.6.2,  
Figure 5-13. From the biological assay it is evident that during the formulation of lysozyme-
loaded GNPs and subsequently crosslinking with diisopropylcarbodiimide, the biological 
activity of encapsulated lysozyme is conserved. For both GTA and DIC-crosslinked GNPs, 
only a small fraction of approximately 11 % is released which seems to be biologically 
inactive (difference between the total amount released and the biologically active amount). In 
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contrast, the enzymatic activity of lysozyme released from glutaraldehyde-crosslinked GNPs 
is significantly lower than the activity of the amount released from the DIC induced surface-
crosslinked GNPs. The lower biological activity and the lower released amount of lysozyme 
in case of glutaraldehyde-crosslinked GNPs can be associated to glutaraldehyde mediated 
gelatin-lysozyme crosslinking which ultimately leads to hindrance in the release of lysozyme. 
On the other hand, the higher release extent and the corresponding higher activity of lysozyme 
from DIC–crosslinked gelatin nanoparticles demonstrates that the apolar crosslinker (DIC) is 
involved to a very lower degree in the inter-molecular crosslink formation between gelatin 
nanoparticulate matrix and the loaded lysozyme. Therefore, it can be extracted that the 
therapeutic activity of loaded protein-based hydrophilic macromolecule is not influenced after  
crosslinking with apolar zero length crosslinker, i.e., diisoproylcarbodiimide. 
 
 




This research work demonstrates a unique and novel approach of stabilization of protein- 
loaded GNPs with the aid of selective surface crosslinking of colloidal interface of GNPs. 
This was possible due to using hydrophobic zero length crosslinker, i.e., 
diisopropylcarbodiimide. Crosslinking of lysozyme-loaded GNPs produced as a result of co-
nanoprecipitation resulted in the formation of GNPs of 200-300 nm with narrow size 
distribution (PDI < 0.2). There is a negligible crosslinking between gelatin nanoparticulate 
matrix and lysozyme as evident from 90-100% release of lysozyme in the release medium. 
The nano-encapsulated polypeptidal compound of lysozyme in DIC-crosslinked GNPs also 
retains its intended therapeutic activity (anti-bacterial activity) after encapsulation and is not 
significantly influenced by the crosslinker during the crosslinking step of particles. In 
contrast, the glutaraldehyde crosslinked GNPs loaded with lysozyme show only 30-40 % 
release of free lysozyme while the remainder 60-70 % is believed to be covalently attached 
with the gelatin nanoparticulate matrix due to glutaraldehyde induced crosslinking. Therefore, 
it can be concluded that the DIC-induced surface-crosslinked gelatin nanoparticles (scGNPs) 
presents an excellent opportunity for the delivery of hydrophilic macromolecules especially 
peptide-based therapeutic compounds. 
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Summary and Outlook 
The efficacy and therapeutic potential of hydrophilic macromolecules especially peptide-
based drugs is limited by different obstacles after administration into the body. Some of these 
obstacles include short biological half, phagocytic clearance, poor membrane permeability 
and instability. In order to overcome these obstacles, one of the promising approaches is the 
nanoparticle-based delivery system. This involves the encapsulation of these hydrophilic 
compounds into hydrophilic polymer-based nanoparticles. Gelatin is one of the 
macromolecular hydrophilic biopolymers which has been predominantly used as a matrix 
material for hydrophilic macromolecular drugs. The main disadvantage of gelatin 
nanoparticles is that they are physicochemically un-stable in aqueous environment. Therefore, 
in order to maintain the structural integrity of these delivery systems in aqueous media, 
different stabilization approaches have been reported. Amongst these approaches, the 
chemical crosslinking has been frequently reported.  
The main disadvantage of chemical crosslinking is that the crosslinker has a potential to 
penetrate inside the nanoparticle matrix thus making the delivery of protein–based drugs less 
flexible because crosslinkers will also react with protein-based drugs. The aim of this research 
work was to design gelatin nanoparticles via nanoprecipitation and subsequently stabilizing 
them with the help of selective interfacial crosslinking to overcome the main drawback for 
flexible protein delivery. For the selective interfacial crosslinking of GNPs, we employed 
diisopropylcarbodiimide (DIC), a zero-length hydrophobic crosslinker. The basic idea is that 
diisopropylcarbodiimide due to its hydrophobicity should not diffuse into the core of 
nanoparticles rather it would establish crosslinks exclusively on the colloidal interface by 
conjugating primary amino groups with the carboxylic functional groups. The effects of 
various critical parameters associated with crosslinking conditions and its possible impact on 
physicochemical properties of nanoparticles were investigated. The concentration of 
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crosslinker, crosslinking time, and temperature of crosslinking mixture were found to be 
critical parameters for the colloidal stability of nanoparticles in aqueous environment. The 
mean hydrodynamic diameter of nanoparticles was also influenced by changing gelatin type, 
its bloom number and concentration in the solvent phase. The surface restricted crosslinking 
behaviour of DIC was assessed in terms of limited crosslinking degree and limited extent of 
participation of the crosslinker (DIC) in the crosslinking reaction.  
During the purification step of these DIC-surface crosslinked GNPs, the problem of non-
redispersibility was observed. The issue was that the pellet formed after centrifugation was 
not redispersed in water despite applying vigorous mechanical shaking as well as ultra-
sonication. This problem was solved with the application of tangential flow filtration. The 
tangential flow filtration was found promising in terms of removing all the unwanted 
impurities from the crude  nanosuspensions of surface-crosslinker gelatin particles. 
The possibility of these surface-crosslinked gelatin nanoparticles (scGNPs) for the delivery of 
hydrophilic macromolecules was demonstrated using both peptide-based payloads, e.g., 
lysozyme as well as non-peptide based payloads, e.g., FITC-dextran with different molecular 
weights. The release from DIC-induced crosslinked gelatin nanoparticles was found to be 
dependent on the molecular weight of FITC-dextran. The release of low molecular weight 
FITC-dextran is characterized by fast burst release followed by a slow release. While, slow 
burst release was observed for high molecular weight FITC-dextran. This release behaviour 
was found to be almost similar to glutaraldehyde-crosslinked GNPs reported in literature [98]. 
In contrast to glutaraldehyde crosslinked GNPs, the rate and extent of FITC-dextran release 
from DIC-crosslinked GNPs was observed to be high. This shows a variability of crosslinks 
formation between glutaraldehyde and DIC-crosslinked GNPs. 
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In order to evaluate the surface restricted crosslinking behaviour in a more realistic way, a 
protein-based payload was necessary. For this purpose, lysozyme was selected as a model 
protein containing many crosslinkable primary amino groups. It was demonstrated that after 
crosslinking of lysozyme-loaded gelatin nanoparticles with DIC, no significant impact of the 
crosslinker was observed on the in vitro release of lysozyme. Approximately, 90-100 % of the 
encapsulated lysozyme was released in PBS (pH 7.4) demonstrating that the crosslinker (DIC) 
does not crosslink the loaded therapeutic protein with the polymeric matrix of gelatin, even 
though both the payload (i.e., lysozyme) and polymer (i.e., gelatin) possess plenty of primary 
amino groups as well as carboxylic groups. Furthermore, the evaluation of biological activity 
of lysozyme released from these surface-crosslinked GNPs demonstrated that the intended 
enzymatic activity of lysozyme, i.e., anti-bacterial activity against gram positive 
microorganisms, is conserved to a significant extent. Therefore, it can be concluded that the 
surface-crosslinking of gelatin nanoparticles using zero length hydrophobic crosslinker (DIC) 
presents an excellent opportunity for the encapsulation of hydrophilic protein-based APIs.  
However, the phenomenon of fast burst release of lysozyme from DIC-crosslinked GNPs 
matrix was observed. This is not surprising as the fast release of low molecular weight 
substances and slow release of high molecular weight substances was already reported in 
literature and this is believed to be due to porous structure of gelatin [189, 190]. Keeping in 
view the release data of FITC-dextran, there exists a specific molecular weight cut-off range 
in the DIC-crosslinked matrix, possibly up to 20 kDa which is equivalent to 4 nm. It is clear 
that lysozyme having molecular weight of 14 kDa is below 20 kDa ~ 4 nm. To overcome the 
fast burst release of low molecular weight macromolecules, it needs further optimization and 
formulation development to control the fast burst release of low molecular weight hydrophilic 
macromolecular payloads. 
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In this context, in order to overcome the fast high burst release phenomenon from surface 
crosslinked GNPs, we are planning to investigate the possible hydrophobization of the surface 
of GNPs via coating the particles with hydrophobic biodegradable polymers such as poly-
(lactic acid). The coating of both un-crosslinked and surface crosslinked GNPs will be 
accomplished with the application of two-step nanoprecipitation [101] and nanoprecipitation-
emulsion solvent evaporation techniques [122]. The idea would be that that the hydrophobic 
coating layer deposited at the interface of GNPs composed of hydrophobic polymers will 
retard the fast burst release of loaded hydrophilic peptides. In this way, the release of 
encapsulated hydrophilic drugs will be prolonged. In parallel, these hybrid NPs composed of 
PLA coated GNPs can be exploited for the delivery of both hydrophobic as well as 
hydrophilic drugs. The hydrophilic drugs will be entrapped in the gelatin core and the 
hydrophobic drugs in the hydrophobic coating composed of poly-(lactic acid). These hybrid 
nanoparticles-based formulations can be used in cancer therapy for the co-administration of 
both hydrophilic and hydrophobic drugs. The co-delivery of hydrophilic and hydrophobic 
drugs in one particle based delivery system has also been reported for cancer treatment using 
other nanomaterials [191]. This coating with biodegradable hydrophobic polymers (i.e., poly-
lactic acid) will not only lead retard the high burst release of low molecular weight 
macromolecules from GNPs but also providing a stabilization mechanism for GNPs in 
hydrophilic environment without chemical crosslinking. 
In order to investigate further the phenomenon of DIC surface crosslinking, we are also 
planning to extend the application of surface-crosslinked gelatin nanoparticles for the delivery 
of other therapeutic proteins, e.g., cytochrome c (apoptosis inducer, anticancer drug), anti-
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